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1. INTRODUCTION 
1.1 Obesity prevalence in childhood 
Overweight and obesity are a major public health concern both in adults and in 
children. In 1997, the World Health Organization has declared obesity a global 
epidemic (WHO, 2001), and the Healthy People 2010 has identified overweight and 
obesity an indicator of the health of a given population (Healthy People, 2000). In fact, 
childhood obesity is most strongly associated to insulin resistance with an increased 
prevalence of type 2 diabetes, dyslipidemia and hypertension at the pediatric age, 
developing to an increased cardiovascular mortality in adulthood (Maffeis et al., 2001). 
The prevalence of obesity in children and adolescents has increased over several 
decades in many industrialized countries (Wang Y. et al., 2006). 
Epidemiological studies of National Health and Nutritional Examination Surveys 
(NHANES) representing United States Population demonstrated that the prevalence of 
obesity between 1971-1974 and 2003-2004 has been increased in pre-school children 
(2-5 yrs) from 5% to 13.9%, from 4% to 18.8% in the age 6-11 years, and from 6.1% to 
17.4% in adolescent age (12-19 yrs) (Figure 1). 
In the last period of observation it has been shown that an increase is present in 
particular ethnic groups like African American or Hispanic American in the scholar and 





































In 2003 the study of Lostein et al. demonstrated that in Europe it is possible to detect 
two apparent trends. The first is the generally lower levels of overweight found among 
children in the countries of central and eastern Europe whose economies suffered 
varying degrees of recession during the period of economic and political transition in 
the 1990s. This has been particularly noticeable in Russia, in Czech Republic and in 
Poland; mainly in rural areas, and among children under age 10, the figure was even 
lower at 7% overweight. The second trend apparent in the data is for the prevalence of 
overweight to be higher among the southern countries of Europe, especially those 
outside of the former eastern bloc. The non-eastern bloc countries surrounding the 
Mediterranean show prevalence rates for overweight children in the range 20–40%, 
while those in northern areas show rates in the range 10–20% (Lobstein et al., 2003, 
Figures 2-3). 
 
Figure 2. Prevalence (percentage) of overweight children aged around 7–11 years 
(higher panel) and 14-17 (lower panel) using the cut-off points recommended by 





Figure 3. Sources of data on the body mass indices of children in Europe. 
 
 
Starting from 2004-2006 the prevalence of childhood obesity in the United States 
remains unchanged at approximately 17% and the rapid increases in obesity 
prevalence previously seen have not continued in this decade and may be leveling off 
(Ogden CL. et al., 2008, Ogden CL et al., 2010). 
Nevertheless NHANES has consistently reported significant differences in obesity 
prevalence by race/ethnicity and among adolescent males but not females of any age. 
This is consistent with previously published results showing an increase in prevalence 
of BMI for age at or above the 97th percentile among males but no change in females 
at any cutoff based on data through 2007-2008 (Figure 4, Ogden CL et al., 2010) 
(Flegal KM et al., 2010). 





Also in Europe recent epidemiological studies demonstrated the achievement of a  
plateau in the prevalence of obesity (Great Britain, France, Sweden) (Olds T. et al., 
2011, Lissner L. et al., 2010, Figure 5). 
 
Figure 5. Percentages of fourth graders with obesity and overweight (+ obesity) with 
95% confidence limits for 4-year changes in Stockholm and Gothenburg, among boys 






More research is needed to understand why these changes may be occurring. 
 
Concerning the Italian picture, a study conducted in 2010 including children and 
adolescents among 6-17 years of age, demonstrated a percentage of overweight and 
obesity of about 26% based on the cut-off proposed by the International Obesity Task 
Force; the study subdivided children in males and females and in three age categories 
(6-9 yrs, 10-13 yrs and 14-17 yrs) (see Table 1).  
 
Table 1. ISTAT study, 2010. Percentage of overweight and obesity in Italy. 
Population 6-9 yrs 10-13 yrs 14-17 yrs Mean 
Males 37,5% 29,1% 20,8% 28,9% 
Females 37,1% 22,0% 11,3% 23,2% 
Total 37,3% 25,6% 16,2% 26,2% 
(statistical information for health promotion, ISTAT, 2011). 
 
Interesting results come from studies on the Piedmont population, comparing school 
children living in Turin in 1977 and in Novara in 1999. After 20 years the percentage of 
obesity increased since 4% in males and 5% in females to 11,64% and 17,24%, 
respectively, in children of 7 years of age; while since 10% in females and 25% in 
males to 22,4 %  and 28.2%, respectively in children of 11 years of age. These data 
confirm previous analysis demonstrating an important increase in pediatric overweight. 
At the end of 2007, the Centre for Disease Control within the Italian Ministry of Health 
commissioned the creation of a national system to estimate the prevalence of 
childhood overweight and obesity by geographic area of Italy (‘OKkio alla SALUTE’ 
project) involving more than 45 000 third-grade students. This project demonstrated a 
high level of childhood obesity in the overall population, 23,6% of overweight and 
12,3% of obesity, which was higher than that of most Western countries; furthermore 
there were substantial geographic differences, with the prevalence of obesity twice as 
high in the south as in the north (49% in Campania and 23% in Valle D’Aosta) (Binkin 
N. et al., 2010) (Table 2 and Figure 6). 
 
















Figure 6. Distribution of body mass index by geographic area for children 8–9 years of 
age, Italy. Cut-offs refer to children 8 years and 10 months of age, the median age of 
the study population (solid line, International Obesity Task Force median; dashed line, 





1.2 Ghrelin system in pediatric obesity 
 
Ghrelin has an emerging role on appetite, glucose and lipid metabolism, and body 
composition and has provided an important strength to this research field opening new 
perspectives within neuroendocrinology and metabolism. In particular it is the only 
known appetite-stimulating hormone in humans and seems one of the principal factors 
involved in appetite, craving and regain weight after weight-loss (Adams CE. et al., 
2011, Delhanty PJ. et al., 2012 ). 
Ghrelin is a 28 amino-acid peptide predominantly produced by the stomach (Kojima M. 
et al., 1999). It has been discovered as the first natural ligand of the orphan GH 
Secretagogue Receptor (GHS-R) type 1a (Kojima M. et al., 1999, van Der Lely AJ. Et 
al., 2004, Kojima M. et al., 2005). Ghrelin presents a characteristic acylation with a 
medium fatty n-octanoic acid on the Ser3 residue (Kojima M. et al., 1999) (Figure 7). 
The n-octanoyl group seems essential for its binding to and activation of the GHS-R1a 
(Kojima M. et al., 1999, van Der Lely AJ. Et al., 2004).  
 




The ghrelin human gene (GHRL) that is located on 3q25-36, encodes a molecule 
named pre-proghrelin of 117 aminoacids (Kojima M. et al., 1999, Kojima M. et al., 
2005) from which derived by alternative splicing also other ghrelin forms, named des-
Gln14ghrelin (Hosoda H. et al., 2000) and In1-ghrelin variant, which retains the GHRL 
intron-1 sequence (Gahete MD. Et al., 2011); both variants can be acylated. Despite 
this background, unacylated ghrelin (UAG), that is devoid of the n-octanoil group at 
Ser3, is the most abundant circulating form (Kojima M. et al., 1999, Kojima M. et al., 
2005, Korbonits M. et al., 2004). Increasing findings demonstrate that also UAG is a 
biologically active molecule. This evidence is consistent with the hypothesis of the 
existence of some GHS-R subtypes that are activated by ghrelin independently of its 
acylation (Caballero B. 2005).  
The mechanism of acylation of the pre-proghrelin or of UAG is largely unknown. Yang 
and coworkers have identified the acyltransferase that octanoylates ghrelin. It has been 
named GOAT (Ghrelin O-Acyltransferase) (Yang J. et al., 2008). From the pre-
proghrelin sequence, another ghrelin-associated peptide of 23 amino acids has been 
found, named obestatin (Zhang JV. Et al., 2005). The first studies have shown that 
obestatin possesses opposing action to ghrelin, inhibiting food intake, weight gain and 
jejunal movement, but the later ones do not fully confirm the previous reports 
(Hassouna R. et al., 2010 ). 
Ghrelin emerged as one of the most powerful orexigenic and adipogenic agents known 
so far (van Der Lely AJ. Et al., 2004, Korbonits M. et al., 2004, Leite-Moreira AF. Et al., 
2007, Cummings DE. et al., 2008, Tschop M. et al., 2000). In all, as a result of central 
and peripheral actions, acylated ghrelin (AG) administration in rodents causes weight 
gain that occurs even in absence of overfeeding (Wiedmer P. et al., 2007). AG 
influences energy balance involving NPY and AgRP in the arcuate nucleus as well as 
decreasing melanocortin tone and reducing the α- and β-melanocyte-stimulating 
hormone by neurons that produce pro-opiomelanocortin (van Der Lely AJ. Et al., 2004, 
Wiedmer P. et al., 2007, Shintani M. et al., 2001, Chen Y. Et al., 2004). Ghrelin 
regulation of energy homeostasis seems also mediated by efferent and afferent fibres 
of the vagal nerve (van Der Lely AJ. Et al., 2004, Wiedmer P. et al., 2007). The active 
vaccination of mature rats with ghrelin immunoconjugates decreases feed efficiency, 
relative adiposity, and body weight gain (Zorrilla EP. Et al., 2006). More recently, by 
acting on GOAT the modification of fatty acid chain length enhances or reduces 
systemic and central chronic actions of AG on adiposity in rodents (Heppner KM. et al., 
2012). On the other hand, the role of UAG in food intake is not fully clarified but it 
seems able to induce a negative energy balance by decreasing food intake and 
delaying gastric emptying via the hypothalamus (Delhanty PJ. et al., 2012). 
In humans ghrelin secretion is pulsatile, with higher secretion night-time; it undergoes 
circadian variations with decreases after food ingestion, thus suggesting a metabolic 
control of it in vivo. Ghrelin could contribute to meal initiation or to nutrient type 
ingestion (van Der Lely AJ. Et al., 2004, Cummings DE. et al., 2006, Heppner KM. et 
al., 2012). The circulating levels of ghrelin are modulated by chronic and acute energy 
imbalance. In fact, ghrelin levels are negatively associated with body mass index; 
ghrelin secretion is increased in anorexia and cachexia, reduced in obesity and 
normalized by recovery of ideal body weight (van Der Lely AJ. Et al., 2004, Leite-
Moreira AF. et al., 2007, Cummings DE. et al., 2008, Tschop M. et al., 2001). More 
recently, GOAT was detected in human circulation in healthy, obese and anorexic 
adults with a positive correlation with body mass index and a negative correlation with 
ghrelin levels, suggesting that GOAT counteracts the adaptive changes of ghrelin 
observed under these conditions (Goebel-Stengel M. et al., 2013). Whether an 
increase of ghrelin levels has been reported after weight loss induced by either diet and 
lifestyle modifications, this increase may help to promote regaining weight. Accordingly, 
GOAT inhibition attenuated food foraging, food intake, food hoarding, and hedonic in 
mice (Teubner BJ. Et al., 2013, Davis JF. Et al., 2012). Furthermore, the overall ghrelin 
profile is partially abnormal in adult obesity: there is absent or changed ghrelin 
elevation during fasting (Perreault M. et al., 2004), abolished or blunted increase during 
the night or sleep deprivation (Yildiz BO. Et al., 2004, Vazquez RMI. Et al., 2006), and 
blunted suppression after a meal (English PJ. Et al., 2002). The only clinical exception 
to this picture seems to be Prader-Willi syndrome (PWS), a genetic disease 
characterized, among many other features, by severe obesity and hyperphagia. 
Interestingly, unlike essential obesity, patients with PWS show elevated ghrelin levels, 
both total and AG levels. Ghrelin hypersecretion has been hypothesized to participate 
in the development of at least some symptoms of PWS syndrome such as hyperphagia 
and weight excess (Yi CX. Et al., 2011).  
As anticipated, circadian ghrelin secretion is profoundly modulated by acute variations 
in the energy balance and nutritional status. Though some stimulatory effects of short-
term fasting on ghrelin secretion has been suggested by some Authors (van Der Lely 
AJ. Et al., 2004, Heppner KM. et al., 2012, Kim MS. Et al., 2003 Muller AF. Et al., 2002) 
but not definitively confirmed (Natalucci G. et al., 2005, Avram AM. Et al., 2005, 
Espelund U. et al., 2005), probably because the assay methods allowing only to 
evaluate total ghrelin levels. Notably, during fasting, AG decreases to nadir levels seen 
post-prandially and UAG remains near to peak levels seen pre-prandially, suggesting 
that long-term fasting inhibits acylation and that this one may be regulated 
independently by nutrient availability in the gut, or esterases which cleave the acyl 
group (Liu J. et al., 2008, Nass R. et al., 2008). In fact, the lipid group that is attached 
by GOAT is likely derived from free fatty acids in the lumen of the gut rather than 
circulation (Kirchner H. et al., 2009). Indeed, with prolonged fasting, AG levels are 
suppressed, whereas UAG is tonic secreted (Liu J. et al., 2008). However, the 
mechanisms mediating the metabolic control of ghrelin secretion are at present still 
matter of debate. Gastric secretion per se has been reported not to play a role, while 
interesting results derive from studies evaluating the effects of nutritional and metabolic 
determinants (van Der Lely AJ. Et al., 2004, Cummings DE. et al., 2008, Yi CX. Et al., 
2011, Prodam F. et al., 2006). The depth and duration of ghrelin decrease after a 
meals is related to the total amount of calories ingested and to the type of the 
macronutrients, in particular carbohydrates and proteins in spite of less effective 
suppression led by lipids (van Der Lely AJ. Et al., 2004, Leite-Moreira AF. et al., 2007, 
Prodam F. et al., 2006). It has also been shown that ingested medium-chain fatty acids 
are directly used for ghrelin acylation, thus theoretically modulating its biological activity 
(Heppner KM. et al., 2012, Nishi Y. et al., 2005). Consistent with its role in nutritional 
status, insulin and glucose seem among the major determinants of ghrelin secretion 
that, in turn, modulates insulin secretion and glucose metabolism as also been 
predicted by the negative correlation between ghrelin levels and body mass index (van 
Der Lely AJ. Et al., 2004, Leite-Moreira AF. et al., 2007, Cummings DE. et al., 2008, 
Tschop M. et al., 2001), and GOAT KO models (Zhao TJ. Et al., 2010).  
Overall, published data suggest that ghrelin acts to optimize energy metabolism in 
period of food restriction as well as preparing the metabolism to percept and use fuel. 
Data derived by rodent models reveal an essential function of ghrelin, perhaps 
accounting for its evolutionary conservation - namely, maintenance of viability during 
periods of famine. Food intake, appetite and energy balance are strictly regulated 
during lifespan with critical changes in each specific period (infancy, adulthood, aging). 
There is increasing evidence, although not conclusive, that some of ghrelin changes 
may contribute to the regulation of food intake and weight also in children, starting from 
neonates.  
 
1.3 Cortisol axis in paediatric obesity 
Cortisol has been reported to have a role in obesity, hypertension, and the altered 
glucose and lipid profile in Cushing’s syndrome, and some studies have suggested that 
moderately increased morning fasting cortisol may be associated with the presence of 
cardiovascular risk factors in adults (Whitworth JA. Et al., 1995, Pasquali R. et al., 
2008, Sukhija R. et al., 2006).  
The metabolic syndrome (MetS) is a cluster of common abnormalities including 
hyperglycemia, abdominal obesity, reduced high-density lipoprotein cholesterol levels, 
and elevated triglycerides and blood pressure (Obunai K. et al., 2007, 2002 NCEP 
report). The components of MetS are associated with endothelial dysfunction and 
atherosclerosis and increase the risk for type 2 diabetes mellitus as well as vascular 
morbidity and mortality (Obunai K. et al., 2007, 2002 NCEP report, Lakka HM. Et al., 
2002, Kolovou GD. Et al., 2007, Athyros VG. Et al., 2004). It is unclear whether a single 
primary abnormality triggers a cascade of diverse events that lead to the manifestation 
of the components of MetS. 
Because the diagnostic features of MetS are shared by Cushing’s syndrome (CS), 
which results from endogenous or exogenous hypercortisolism, it was proposed that 
cortisol contributes to the pathogenesis of both states although only mild 
hypercortisolism occurs in MetS in contrast with CS (Pasquali R. et al., 2006, Walker 
BR. Et al., 2006). 
In adults some studies suggest that circulating cortisol concentrations are higher in 
patients with MetS compared with healthy subjects, in particular in patients  with 
hypertension or impaired glucose tolerance (Sen Y. et al., 2008, Duclos M. et al., 2005, 
Weigensberg MJ. Et al., 2008, Phillips DI. Et al., 1998, Misra M. et al., 2008) (Figure 8, 
Walker BR. Et al., 2006).  
Furthermore subjects presenting visceral obesity possess an hyperactivity of HPA axis 
with a functional hypercortisolism (Pasquali R. et al., 2000). 
 
 
Figure 8. Positive correlations between 09.00 h fasting plasma cortisol and features of 
the metabolic syndrome. Results are from 370 men aged 59–70 years studied in 





Reinher and Andler found significant associations between the degree of cortisolemia 
and fasting insulin levels in obese children, and levels of both hormones decreased 
following weight loss (Reinher and Andler, 2004). 
Abnormalities in the central regulation of the hypothalamic-pituitary-adrenal (HPA) axis 
due to stress may lead to a mild hypercortisolism in adults with obesity and metabolic 
syndrome (Walker BR. Et al., 2007, Anagnostis P. et al., 2009). 
Two recent studies in overweight Latino youths with a family history of type 2 diabetes, 
confirmed higher fasting cortisol levels in those with lower insulin sensitivity (Walker 
BR. Et al., 2006) or metabolic syndrome, and an association with hypertension and 
high glucose levels (Sen Y. et al., 2008). However, a study in a small group of 
prepubertal children showed higher morning plasma cortisol levels in those with higher 
total cholesterol and triglycerides (Duclos M. et al., 2005). 
These findings suggested that, in children, there are similar mechanisms to those 
reported in adults, but higher cortisol levels could be first a consequence rather than a 
cause of comorbidities in obesity (Reinher and Andler, 2004).  
It is also to be emphasized that in CS, once the tumor is removed and consequently 
glucocorticoid excess, symptoms improve; in the MetS, weight loss reverses both 
hypercortisolism and phenotypic abnormalities (Obunai K. et al., 2007, 2002 NCEP 
report, Lakka HM. Et al., 2002, Kolovou GD. Et al., 2007, Athyros VG. Et al., 2004, 
Prodam F. et al., 2011) and improves insulin resistance (Prodam F. et al., 2011).  
Despite the fact that cortisol levels are within the normal range, there is evidence of 
increased activity of cortisol in the periphery and dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis (Walker BR. Et al., 2006, Sen Y. et al., 2008).  
The pathogenesis of the activation of HPA axis in metabolic syndrome remains unclear. 
It could be in part mediated by a pro-inflammatory state which characterize the obesity 
state. In fact it is known that cortisol secretion increase in response to inflammatory 
states and interleukin-6 levels, increased in overweight subjects, are negatively 
correlated to the cortisol–binding-globuline (CBG) levels (Bernier J. et al., 1998). It has 
also been demonstrated that CBG levels negatively correlate to BMI (Gagliardi L. et al., 
2010). Therefore a reduction in CBG concentration in obese patients could be an 
explanation for the higher cortisol concentration in obesity. Recently it has been 
demonstrated that CBG is present also in the anterior pituitary and in supraoptic and 
paraventricular nuclei, where it is suggested to have a role in HPA axis regulation 
(Henley DE. et al., 2011). Other cytokines produced in adipose tissue instead 
stimulates enzymatic activity of 11β-hydroxysteroid dehydrogenase1 (11βHSD1) which 
convert the metabolically inactive corticosterone in cortisol (Wake DJ. Et al., 2003). 
Higher levels of 11 βHSD1 mRNA have been demonstrated In obese subjects 
compared to that in normal weight subjects (Mariniello B. et al., 2006). 
Furthermore in obese subjects higher leptin levels have been demonstrated. Leptin is a 
peptide produced by adipose tissue which possess an important role in appetite and 
metabolism regulation, but also induce an increase in glucocorticoid secretion (Nelson 
DL. Et al., 2006). 
Therefore it seems that different pathophysiological mechanisms could contribute to a 
dysregulation of HPA axis in obesity state. 
Although cortisol is associated with metabolic alterations, it appears that 
adrenocorticotropic hormone (ACTH) may directly contribute to comorbidities in obesity. 
It has been shown in vitro that ACTH interacts with adipocytes, promotes insulin 
resistance and is pro-inflammatory (Iwen KA. Et al., 2008). To date, however, the role 
of ACTH has not been determined in obese children.  
2. EXPERIMENTAL RESULTS 




Acylated and unacylated ghrelin levels in normal weight and obese 




Aim of the Study 
 
In order to understand the biological implications of acylated (AG) and unacylated 
(UAG) ghrelin in the pediatric population, we evaluated AG and UAG levels in normal 
weight and obese children, prepubertal and pubertal. Furthermore we measured 
insulin, leptin and adiponectin levels in the same subjects. 
Subjects and Methods 
It has been evaluated a total 140 children followed by the Division of Pediatrics of our 
Hospital, “Azienda Ospedaliero Universitaria Maggiore della Carità” in Novara, Surgery 
of Pediatric Endocrinology and Auxology.  
All subjects underwent a clinical evaluation by a trained research team. Pubertal stages 
were determined by physical examination, using the criteria of Marshall and Tanner 
(Appendix 1). Height was measured to the nearest 0.1 cm using a Harpenden 
stadiometer, and body weight with light clothing to the nearest 0.1 kg using a manual 
weighing scale. Body mass index (BMI) was calculated as body weight divided by 
squared height (kg/m2). Children were subdivided using Italian growth charts (Cacciari 
E. et al., 2006, Appendix 2). We considered obese children with BMI above the 95th 
percentile. Waist circumference was measured at the high point of the iliac crest around 
the abdomen and was recorded to the nearest 0.1 cm (Appendix 3). Systolic BP (SBP) 
and diastolic BP (DBP) were measured three times at 2-minute intervals using a 
mercury sphygmomanometer with an appropriate cuff size after participants were 
seated quietly for at least 15 minutes, with their right arm supported at the level of the 
heart and feet flat on the floor, prior to other physical evaluations, and at least 30 
minutes after blood sampling, using a standard mercury sphygmomanometer. Mean 
values were used for the analyses. Hypertension was determined if BP values recorded 
on enrollment day and on blood samples day are always elevated. (Appendix 4). 
Normal weight children presented to the clinic for an evaluation of growth, pubertal 
status, suspected thyroid disease, general health checkup, but no disease was 
confirmed at the end of the evaluations. Exclusion criteria were the presence of any 
psychiatric or organic diseases in particular neurological, endocrine (short stature), 
liver, and kidney abnormalities. Nobody was under pharmacological treatments. The 
study protocol was approved by an Independent Ethical Committee and the informed 
consent had been obtained from each children’ parents.  
After a 12-hour overnight fast, children arrived at the clinical center at 7.30 AM and 
rested comfortably for half an hour prior to blood testing. At 8.00 AM, blood samples 
were taken for measurement of plasma AG, UAG, leptin, adiponectin, glucose, insulin, 
testosterone (in males) or estradiol (in females). 
Human ghrelin (fm/ml) was measured by ELISA (DRG Instruments GmbH, Marburg, 
Germany). Acylated ghrelin: sensitivity: 1 fm/ml. Intra- and inter-assay CV ranges:3.5-
3.8% and 2.6-3.9%. Unacylated ghrelin: sensitivity 10 fm/ml Intra e inter-assay CV 
ranges: 2.1-4.7 % and 4.2-7.2%. 
Insulin (μUI/ml; 1μUI/ml = 7.175 pmol/l) was measured by a chemiluminescent enzyme-
labelled immunometric assay (Diagnostic Products Corporation, Los Angeles, CA). 
Sensitivity: 2 μUI/ml, with an intraand inter-assay CV range: 2.5-8.3 and 4.4-8.6%. 
Plasma glucose levels (mg/dl; 1 mg/dl:0,05551mMol/liter) were measured by the gluco-
oxidase colorimetric method (GLUCOFIX, by Menarini Diagnostici, Florence, Italy). 
Adiponectin was measured by an ELISA kit E09, (Mediagnost, Reutlingen, Germany). 
Sensitivity: 0.06 μg/ml, with an intra e inter-assay CV range: 4.7% e 6.7%. 
Leptin was measured by Direct ELISA (Diagnostics Biochem Canada). Sensitivity: 0.5 
ng/ml. Intra e inter-assay CV ranges: 7.4% e 8.7%. 
Testosterone and estradiol were measured with Centaur instrument, Siemens kit, by 
chemiluminescent method. Testosterone: sensitivity 10 ng/dl, with an inter-assay: 6.2%; 
estradiol: sensitivity 7 pg/ml, with an inter-assay: 7.4%. 
Insulin resistance was calculated using the formula of HOMA-IR = [fasting glucose 
(mg/dL)/18 ×fasting insulin (mUI/L)]/22.5. Beta cell function at fasting was calculated 
using the formula of HOMA-B =(20×fasting insulin)/(fasting glucose-3.5). 
Insulin sensitivity fasting was calculated from the QUICKI index (1/[log fasting insulin + 
log fasting glucose]) (26). 
Data are expressed as mean±SD or median and 25th-75th percentiles. For continuous 
variables, the variation between groups was compared by means on nonparametric 
Wilcoxon and Mann-Whitney U tests, where appropriate. A correlation analysis was 
performed using the Pearson’s correlation test thought a logarithmic transformation of 
the parameters when necessary. A partial correlation analysis was performed to adjust 
for BMI, age, gender, and pubertal status. A stepwise regression model with two-tailed 
probability values and 95% confidence intervals for each significant parameter in the 
correlation analysis was used to measure the strength of association between 
variables. 
Statistical significance was assumed for p<0.05. All statistical analyses were performed 
with SPSS for Windows version 15.0 (SPSS INC; Chicago, IL, USA). 
Results 
Hormonal parameters 
Eighty-two children (mean±SD) (age: 9.7 ± 4.1 yr) were normal weight (NW): 46 
females and 36 males, 44 prepubertal children and 38 with pubertal stage from II to V. 
The remaining 58 children (age (mean±SD): 9.8±3.4 yr) were obese (OB): 30 females 
and 28 males, 28 prepubertal and 30 pubertal children. All auxological parameters of 
two groups are reported in Table 3. 
 






We observed that the median (IQR) of AG (6.5; 3.2-12.0 fmol/ml) in NW was higher 
(p<0.02) than in OB (4.4; 1.4-8.1 fmol/ml) (Fig.1). Likewise, the median of UAG (120.1; 
80.4-172.3 fmol/ml) in NW was higher (p<0.0001) than in OB (61.3; 45.9-98 fmol/ml) 
(Figure 9), while the AG/UAG ratio was similar for both groups. 
 
Figure 9. AG (fmol/ml), UAG (fmol/ml) levels and AG/UAG ratio in normal weight (NW) 








No differences in ghrelin levels were found between males and females. 
Interestingly in NW, AG and UAG were higher in prepubertal than in pubertal children 
(8.2 vs 4.6 fmol/ml and 155.0 vs 97.2 fmol/ml, p<0.01), with a similar profile observed in 






Figure 10. AG (fmol/ml) and UAG (fmol/ml) levels in normal weight (NW) and obese 






Therefore AG/UAG ratio were similar in prepubertal and in pubertal children, either in 





















































Figure 11. AG/UAG ratio in normal weight (NW) and obese (OB) children, prepubertal 















When metabolic parameters were evaluated, it was observed that adiponectin levels 
were higher (p<0.0001) in NW (14.7; 10.2-19.9 μg/ml) than in OB (9.2; 6.6-11.3 μg/ml), 
whereas in contrast leptin levels in NW (6.9; 4.7-11.9 ng/ml) were lower (p<0.001) than 
in the OB group (36.2; 23.8-50.0 ng/ml) (Fig.4). It was observed that insulin levels in 
the NW group (5.3; 3.1-8.1 μUI/ml) were lower (p<0.001) than in OB (12.9; 8.1-18.2 
μUI/ml). 
 
No gender differences were observed for adiponectin and insulin, while leptin levels in 
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During pubertal development in both NW and OB children, adiponectin levels were 
significantly lower (p< 0.005), while leptin levels were higher in pubertal when 
compared to prepubertal children (p<0.0001). Insulin levels were higher in OB pubertal 
than prepubertal (p<0.01), while in NW they increased during puberty, but this variation 
did not reach the statistical significance (Figure 12). 
 
 
Figure 12. Adiponectin, leptin, insulin levels in normal weight (NW) and obese (OB) 
























































































































P P  N W
P  N W
P P  O B
P  O B
NW showed HOMA and HOMAβ indices lower than OB (p<0.0001) with a QUICKI 
index higher (p<0.0001). 
Glucose levels maintained similar levels between groups. As expected, in both groups 
testosterone and estradiol levels increased with puberty (p<0.0001 and p<0.01, 
respectively). 
HOMA and HOMAβ were higher and QUICKI index lower in puberal children than 
prepubertal in both groups (p<0.0001). 
 
Correlation and regression analysis 
When correlation analyses were performed in all the subjects together, it was found 
that both AG and UAG were negatively correlated with age, height, weight and BMI 















Table 4. Pearson coefficients using correlation analysis for AG and UAG levels in all 
subjects. a:p<0.05; b:p<0.01; c:p<0.001; d:p<0.0001 
 
We observed that AG was negatively correlated with leptin and insulin (p<0.001) and 
showed a weak positive correlation with adiponectin (p<0.05). UAG showed a negative 
correlation with leptin, testosterone, estradiol, glucose and insulin levels (p<0.001), with 
a stronger positive correlation with adiponectin levels (p<0.0001) (Figures 13-14). 
 
















AG and UAG were negatively correlated with HOMA and HOMAβ (p<0.0001), and 
positively with QUICKI (p<0.0001). 
AG maintained the negative correlation with leptin and insulin (p<0.0001) when 
correcting for pubertal stage, and only with insulin (p<0.001) when corrections were 
made for pubertal stage and/or BMI. UAG showed a negative correlation with 
adiponectin, leptin and insulin (p<0.0001), when correcting for pubertal stage, whereas 
correlations were maintained for leptin and insulin (p<0.001) when correcting for 
pubertal stage and/or BMI. 
Analyzing the two groups separately, AG and UAG were negatively correlated with age, 
height, weight and BMI (p<0.0001) in OB children. UAG was correlated with 
anthropometric parameters (p<0.01) in NW, not AG. Moreover AG and UAG showed 
the same correlations with metabolic parameters and insulinemic indices, with 
exception of adiponectin. Only UAG was correlated with adiponectin in both OB 
(p<0.02) and NW (p<0.0001) children. Moreover, AG was negatively correlated with 
insulin (p<0.05) when corrected for pubertal stage, whereas UAG maintained its 
negative correlation with insulin and leptin (p<0.0001) in both groups. AG kept its 
correlation with insulin only in OB group, not in NW, and UAG with insulin and leptin 
(p<0.001) in OB group and with insulin (p<0.0001) in NW group when corrected for 
pubertal stage and/or BMI. In normal weight children auxological parameters resulted 
not correlated with AG levels. 
Multiple regression analysis revealed that AG levels were negatively predicted (R2: 
0.214; p<0.001) by insulin (standardized β: -0.462; unstandardized β: -0.379; IC 95% -
0.516/-0.241), when corrected for pubertal stage or BMI. UAG levels were negatively 
predicted (R2: 0.407; p<0.0001) by BMI (β: -0.553; unstandardized β: -5.386; IC 95% -
6.919/-3.853) and insulin (β: -0.271; unstandardized β: -1.999; IC 95% -3.381/-0.618) 
and positively by adiponectin (β: 0.260; unstandardized β: 2.467; IC 95% 0.881/4.053) 
when corrected for pubertal stage. Alternatively, UAG levels were negatively predicted 
(R2: 0.422; p<0.0001) by insulin (β: -0.571; unstandardized β: -5.150; IC 95% -6.549/-
3.750) and leptin (β: -0.224; unstandardized β: -0.479; IC 95% -0.903/-0.056) and 
positively predicted by adiponectin (β: 0.277; unstandardized β: 2.640; IC 95% 
1.153/4.127) when corrected for BMI. 
Discussion 
The present study demonstrates that obese children show AG and UAG levels lower 
than those in normal weight children; this reduction is similar between the two forms, 
with maintenance of the same AG/UAG ratio. We observed that ghrelin levels are lower 
during puberty in both groups, with no differences emerging for gender. Interestingly, 
when the two ghrelin forms were evaluated separately, a peculiar yet strong 
relationship between UAG levels and metabolic parameters has been observed, 
suggesting a significant role for UAG in metabolic functions. 
To the present day, only few studies have reported AG and UAG levels in childhood, 
being mainly focused on adolescents and small cohorts of subjects (Harada T. et al., 
2008, Mackelvie KJ. Et al., 2007). To our knowledge, this is the only larger study 
evaluating both forms of ghrelin in obese and healthy children and it clearly shows 
lower levels of both AG and UAG in the obese state. 
Circulating ghrelin is comprised primarily of UAG (Van der Lely AJ. Et al., 2004, Soares 
JB. Et al., 2008), however, at present the regulation of the different forms of ghrelin is 
poorly understood. In adulthood it has been demonstrated that both forms of ghrelin are 
similarly inhibited by feeding, while in the fasting state a dissociation of the two forms is 
evident (Soares JB. Et al., 2008). During long-term fasting, AG levels decrease while 
UAG and total ghrelin remain unchanged (Soares JB. Et al., 2008, Liu J. et al., 2008). 
Available data in adulthood suggest that AG and UAG may have different and opposite 
effects on glucose homeostasis, where AG, most likely via GHS-R1a receptors, inhibits 
insulin secretion thus increasing glucose levels and exerting a direct effect on 
hepatocytes to modulate gluconeogenesis and glycogen synthesis (Van der Lely AJ. Et 
al., 2004). In contrast, UAG counteracts the AG effect on insulin secretion via as yet to 
be described receptors (Wiedmer P. et al., 2008). 
In accordance with this data, in our study OB children show lower levels of both AG 
and 
UAG when compared to NW subjects, either in prepubertal or in pubertal children 
maintaining the same AG/UAG ratio during childhood. In both groups AG, but more 
strongly UAG, correlated with adiponectin, leptin, insulin. Furthermore both forms are 
well related with insulinemic indices, negatively with HOMA and HOMAß and positively 
with QUICKI. Also when corrected for pubertal stage and BMI, AG levels were 
negatively predicted by insulin while UAG were predicted by insulin, leptin and 
adiponectin. The consensual reduction independent of pubertal stage of AG and UAG 
in obesity without modification of the AG/UAG ratio, as well as a negative correlation of 
both forms with insulin metabolism, further suggests that all the ghrelin secretion is 
strictly modulated by insulin lifespan. Analyzing the two groups separately both AG and 
UAG maintained their correlations with insulin levels and indices, while only UAG was 
correlated with adiponectin levels suggesting their interplay metabolic functions in 
children. In normal weight children auxological parameter resulted not correlated with 
AG levels, probably due to the little number of subjects or skewed distribution. 
The regulation of AG and UAG circulating levels has not yet been clearly defined. It is 
thought that UAG could be produced directly from the ghrelin gene, therefore via a 
different pathway to the acyl form, or alternatively it could be derived by the deacylation 
of ghrelin (Soares JB. Et al., 2008, Liu J. et al., 2008 ). 
Very recently GOAT, an enzyme catalyzing the addition of the octanoyl-group has been 
identified (Gualillo o. et al., 2008). It is not known at present whether the GOAT levels 
regulate changes in ghrelin acylation or, on the contrary, if GOAT itself depends on 
different metabolic conditions. Its discovery has introduced intriguing questions and 
new possibilities to understanding better the regulation of energy balance. 
As such, the presently published data demonstrates that total ghrelin does not 
adequately reflect AG and UAG ghrelin levels, suggesting a role of ghrelin acylation in 
the modulation of energy intake (Harada T. et al., 2008). In this context, the 
measurement of AG/UAG ghrelin ratio could be a more useful tool to understanding 
ghrelin changes in different conditions. In our study, we observed that both forms of 
ghrelin did not show gender differences. Most studies are concordant with our results 
(Purnell JQ. Et al., 2003,  Vilarrasa N. et al., 2005), but some have demonstrated that 
they are modulated by sex. For example, adult women studied in the late follicular 
phase showed higher levels of ghrelin with respect to men of a similar age and BMI 
(Van der Lely AJ. Et al., 2004). Studies evaluating total ghrelin levels in children are 
more homogeneous and confirm the present results (Bellone S. et al., 2004, Whatmore 
AJ. et al., 2003). Of particular relevance is the study by Ghizzoni et al. which 
demonstrated in prepubertal children that within a 24 hour period, ghrelin is secreted in 
a pulsatile manner and with a circadian rhythm, showing no differences for 
gender (Ghizzoni L. et al., 2004). 
In the present study, AG and UAG ghrelin levels are lower during pubertal 
development, reflecting the pattern for total ghrelin as previously observed in normal 
weight children during puberty (Soriano-Guillen L. et al., 2004, Whatmore AJ. et al., 
2003). When correcting for pubertal stage, AG maintains the negative correlation 
exclusively with insulin, while UAG showed a negative correlation with adiponectin, 
leptin and insulin. 
To date, the physiological mechanisms for the regulation of ghrelin secretion is not yet 
fully understood. More certainly the gonadal system appears to play a role, with GHS 
receptors identified in the ovary and testis, with Leydig cells shown to synthesize 
ghrelin (Gil-Campos M. et al., 2003). Studies in polycystic ovary syndrome, a condition 
of hyperandrogenism, and in hypogonadal males support the hypothesis of a role of 
androgens on ghrelin secretion (Pagotto U. et al., 2002, Pagotto U. et al., 2003). 
Lebenthal et al. also studied total ghrelin levels before and after priming with sexual 
steroids (Lebenthal Y. et al., 2006) demonstrating, in male subjects, a clear reduction in 
circulating ghrelin levels while no changes were observed in females. In line with these 
findings, we observed in the present study that both ghrelin forms were similarly lower 
during pubertal development and their levels negatively correlated with circulating 
testosterone and estradiol levels. On the other hand this different hormonal pattern 
could be due to changes in body composition, characteristic of puberty. Body 
proportions and fat distribution change over pubertal period due to differences in 
endocrine status, genetic factors, ethnicity and the environment with males assuming 
an android and females a gynecoid shape, respectively. In fact, during puberty, males 
gain greater amounts of lean and skeletal mass whereas females mainly acquire fat 
mass (Loomba-Albrecht LA. et al., 2009). 
During puberty we also observed lower adiponectin levels and higher leptin levels in 
both groups. Insulin levels are higher only in obese children, not in normal weight ones 
with glucose maintaining similar levels. This effect is probably due to an increase in 
body fat mass that is correlated with the insulin secretion.The regulation of body weight 
and energy homeostasis is a complex system that involves signals converging on the 
central nervous system. The hypothalamic nucleus such as the arcuate nucleus, 
ventral tegmental area and the substantia nigra are the primary sites where peripheral 
signals are integrated for the control of weight balance (Van der Lely AJ. Et al., 2004, 
Gil-Campos M. et al., 2003). It has been demonstrated that ghrelin as well as other 
anorectic peptides signal to the same system exerting opposite functions. A negative 
relationship between leptin and ghrelin has been shown in several studies (Tolle V. et 
al., 2003, Weigle DS. Et al., 2003, Loomba-Albrecht LA. et al., 2009), with leptin being 
able to inhibit gastric ghrelin secretion (Kalra SP. Et al., 2005). To date, the existence 
of a negative feed-back between these two hormones is still matter of debate. In 
addition there is evidence that adiponectin levels are lower in obese subjects and 
increase with weight loss while being directly correlated to insulin sensitivity (Svarbrick 
MM. et al., 2008). This correlation is lost after matching for pubertal development 
suggesting a different role for puberty on these two peptides. In the same 
population, adiponectin was positively correlated with AG and UAG levels. When 
correcting for puberty and BMI, we observed that AG was negatively correlated with 
insulin, while UAG was predicted primarily by leptin in OB and insulin in NW, 
suggesting diverse roles for the two forms of ghrelin in metabolism and gonadal 
maturation. The loss of correlation between UAG and leptin at puberty in NW but not in 
OB suggests that puberty is a key modulator of ghrelin, more specifically UAG with the 
data confirming the role of leptin as a trigger of gonadal maturation with implication of 
leptin- and insulin-resistance in obesity (Chan JL. Et al., 2001). The positive correlation 
between UAG and adiponectin, independent of puberty, strongly suggests a common 
metabolic regulation. 
In conclusion the present study demonstrates in a large cohort of subjects that AG and 
UAG levels in obese children are lower than those in normal weight ones, with the 
same ratio between the two forms maintained. While no gender differences were 
observed, the levels of both ghrelin forms were comparable lower during puberty, 
suggesting the same inhibitory influence by sexual hormones on AG and UAG. 
Importantly, a separate evaluation of AG and UAG demonstrated a peculiar strong 
relationship between UAG levels and metabolic parameters suggesting a role for UAG 
in metabolic functions. Further studies focusing on the feeding state are needed to 
increase knowledge of the role of ghrelin acylation on energy homeostasis. Importantly, 
we feel that for clinical purposes the measurement of AG/UAG ratio should be a more 
useful tool in understanding the variation of ghrelin under different conditions. 
2.2 Study 2 
 
Title 
Acylated/unacylated ghrelin ratio in cord blood: correlation with 
anthropometric and metabolic parameters and pediatric lifespan 
comparison 
 
Aim of the Study 
 
We hypothesize that, at birth, AGA NN show ghrelin levels similar to prepubertal 
children, with the same AG/UAG ratio. To understand the lifespan regulation and the 
biological implications of the two ghrelin forms at the neonatal age, we evaluated AG 
and UAG levels at birth compared with those of NW and OB children, both prepubertal 
and pubertal. 
Subjects and Methods 
We studied three groups of consecutive Caucasian subjects: neonates (NN), normal 
weight children (NW), and obese (OB) children according to Italian growth charts 
(Cacciari E. et al., 2006, Appendix 2). Group of newborn was composed of adequate 
for gestational age (AGA) Caucasian NN. AGA was defined as a birth weight from the 
10th to the 90th percentile for gestational age according to Italian charts (Appendix 5). 
All babies were born after uncomplicated pregnancies by vaginal or cesarean delivery 
and were otherwise healthy. All the mothers were healthy and in particular none of the 
mothers had gestational diabetes. None of the babies showed signs of distress at 
delivery. Birth weight and length were recorded at birth by the attending nurse. 
This neonatal population has been compared to the pediatric population described in 
study 1. Group NW included 82 children (46 females and 36 males) born AGA. Of 
these 44 were prepubertal and 38 in a pubertal stage from II to V according to Tanner 
scale (Appendix 1). NW subjects have their weight included between the 3rd and 75th 
percentile of Italian charts (Appendix 2). Group OB was composed of 58 children (30 
females and 28 males), 28 of which were prepubertal and 30 pubertal. All OB children 
were born AGA. All NW and OB children were randomly enrolled according to the 
clinical criteria at Division of Pediatrics, University of Piemonte Orientale, Novara, Italy. 
Exclusion criteria were the presence of any psychiatric or organic diseases in particular 
neurological, endocrine (short stature), liver, and kidney abnormalities. 
None of the children were under pharmacological treatments. The study protocol was 
approved by an Independent Ethics Committee and the informed consent was obtained 
from each child’s parents. 
Auxological measurements on children have been described in study 1. In cord blood 
at birth in NN, and at 0830–0900 h following an overnight fast in NW and OB plasma, 
we measured AG, UAG, and insulin. The AG/UAG ratio was calculated. In NN, at 
delivery, the cord was immediately clamped and venous blood samples were drawn by 
catheterization. 
Human ghrelin (fmol/ml) was measured in acidified plasma stored at K80 8C using 
ELISA kits from DRG Instruments GmbH, Marburg, Germany. AG: sensitivity: 1 fmol/ml 
intra- and inter-assay coefficient of variation (CV) ranges: 3.5–3.8 and 2.6–3.9% and 
UAG: sensitivity: 10 fmol/ml intra- and inter-assay CV ranges: 2.1–4.7 and 4.2–7.2%. 
Insulin (mUI/ml; 1 mUI/mlZ7.175 pmol/l) was measured by chemiluminescent enzyme-
labeled immunometric assay (Diagnostic Products Corporation, Los Angeles, CA, 
USA). Sensitivity: 2 mUI/ml intra- and inter-assay CV ranges: 2.5–8.3 and 4.4–8.6%. 
Data are expressed as mean ± S.E.M. Distributions of continuous variables were 
examined for skewness and were logarithmically transformed, where appropriate. 
Differences between the groups were assessed by the Student’s t-test or the one-way 
ANOVA with post-hoc analysis by the Bonferroni test. A correlation analysis was 
performed by the Pearson’s correlation test. Statistical significance was assumed for 
P!0.05. All statistical analyses were performed with SPSS for Windows version 15.0 
(SPSS, Inc., Chicago, IL, USA). 
Results 
Group of newborn was composed of 82 Caucasian NN (40 males and 42 females), 
born to term (37–41 weeks of gestation) and adequate for gestational age with a 
normal ponderal index. Thirty-eight were born by vaginal delivery and 44 from cesarean 
delivery. 
All auxological parameters of the three groups  are reported in Table 5. 
 
Table 5. Clinical parameters of NN, NW and OB children. 
 
 
AG levels (mean±S.E.M.) were lower in NN compared with both NW (1.68±0.24 vs 
8.43±0.87 fmol/ml; P<0.0001) and OB children (1.68±0.24 vs 5.30±0.68 fmol/ml; 
P<0.0001; Fig. 1). AG levels were particularly lower in NN than in prepubertal NW and 
OB children (9.77±1.06 and 6.23±0.73 fmol/ml, respectively; P<0.007). UAG levels 
were higher in NN (213.2±9.1 fmol/ml) compared with NW (135.9±8.7 fmol/ml; 





Figure 15. Acylated and Unacylated ghrelin levels in neonates and in normal weight 
(NW) and obese (OB) children, prepubertal (PP) and pubertal (P) 
Furthermore, AG/UAG ratio was lower in NN than in NW (0.01±0.0 vs 0.07±0.01; 
P<0.0001) and OB children (0.01±0.0 vs 0.07±0.01; P<0.0001). AG/UAG ratio was 
similar between NW and OB (Figure 16). 
 
Figure 16. AG/UAG ratio in neonates and in normal weight (NW) and obese (OB) 





No gender differences have been found (Figure 17). 
 






NN showed insulin levels (6.40±0.76 mUI/ml) similar to NW (6.26±0.51 mUI/ml) and 
lower than OB children (14.4±G1.24 mUI/ml; P<0.0001). 
AG, UAG levels and the AG/UAG ratio were not different in NN according to the type of 










Figure 18. Acylated, Unacylated ghrelin levels and AG/UAG ratio in neonates born 
from cesarean or vaginal delivery. 
 
No gender differences were detected in each of the three groups. 
At birth UAG was positively correlated with AG (Pearson: 0.425; P<0.0001) and 
negatively with insulin (-0.253; P<0.02). No association was found between UAG and 
anthropometric parameters. AG did not demonstrate any associations with 
anthropometric or hormonal parameters, with the exception of UAG. In NW and OB, 
UAG was positively correlated with AG (0.537; P<0.0001) and negatively with insulin 
and BMI (-0.566 and -0.541; P<0.0001). Similarly, AG was positively correlated with 
UAG and negatively with insulin and BMI (-0.442 and -0.323; P<0.0001).  
In a model composed of all three groups, UAG was negatively correlated with weight 
and insulin (β: -0.661 and -0.489, respectively; P<0.0001) and AG was weakly 
associated in a negative manner exclusively with insulin (β: -0.214; P<0.003). 
Discussion 
Our study is mainly focused on a physiological investigation of the two forms of ghrelin, 
AG and UAG, in healthy AGA newborns compared with later in life. The results 
demonstrate that in full-term NN, the venous cord blood at birth presents a very 
different profile of the two ghrelin forms compared with that found in children. NN show 
lower AG and higher UAG levels than NW and OB children, independent of pubertal 
status. As a consequence, the AG/UAG ratio in cord blood of NN is lower compared 
with that found in NW and OB children. 
To date, most authors have studied total ghrelin independent of the two forms in NN 
and children (Soriano-Guillen L. et al., 2004, Ng PC. Et al., 2005, Chanoine JP. Et al., 
2003, Chanoine JP. Et al., 2002, Kitamura S. et al., 2003, Farquhar J. et al., 2003, 
Whatmore AJ. Et al., 2003), with a few studies published regarding the ghrelin 
isoforms, particularly in newborns. 
It has been clearly demonstrated that total ghrelin levels are similar in female and male 
newborns (Soriano-Guillen L. et al., 2004, Martos-Moreno GA. Et al., 2009, Pirazzoli P. 
et al., 2005, Bellone S. et al., 2003) and are higher in SGA compared with AGA 
newborns (Onal EE. Et al., 2004, Kitamura S. et al., 2003, Farquhar J. et al., 2003), 
while controversial data exists regarding correlations between ghrelin levels and 
gestational age or auxological parameters (Martos-Moreno GA. Et al., 2009, Farquhar 
J. et al., 2003, Chiesa C. et al., 2088, Bellone S. et al., 2004). Soriano-Guillen et al. 
(Soriano-Guillen L. et al., 2004) demonstrated that 
total ghrelin levels in newborns were similar between full term and preterm, increasing 
during early postnatal life and decreasing thereafter during puberty with a negative 
correlation between ghrelin, age, and Tanner stages. 
Only a few studies have shown that AG is present in fetal and neonatal circulation 
(Martos-Moreno GA. Et al., 2009, Pirazzoli P. et al., 2005, Bellone S. et al., 2004) 
equally between preterm and SGA newborns, and full term and AGA, without 
differences with respect to gender. Moreover, no correlations were found between AG 
and auxological parameters (Martos-Moreno GA. Et al., 2009, Pirazzoli P. et al., 2005, 
Lanyi E. et al., 2004). Recently, Mendez- Ramirez et al. (Mendez-Ramırez F. et al., 
2009) measured UAG levels in AGA and SGA newborns at the age of 1 week of life, 
showing that UAG was higher in SGA compared with AGA NN. To date, no authors 
have studied UAG levels in cord blood. In our study, we opted to use an assay based 
on a double-antibody sandwich technique where a monoclonal antibody specific to the 
C-terminus of ghrelin is coated onto the multiwell plate and detection is performed by 
an acetylcholinesterase labeled antibody specific to the N-terminus of ghrelin, therefore 
sandwiching AG when present. This ELISA kit has been demonstrated to have greater 
assay specificity, particularly with respect to nutritional states (Prudom C. et al., 2010). 
Using the same assay, we have previously discussed data related to AG and UAG in 
prepubertal and pubertal NW and OB children (Bellone S. et al., 2004, study 1). In this 
study, our data demonstrates that the AG/UAG ratio is very different in the venous cord 
blood of NN compared with later in life, demonstrating lower AG and higher UAG levels 
than NW and OB children. Interestingly, AG/UAG ghrelin ratio is lower in NN than in 
children, considering the prepubertal age and pubertal age. This is supported by 
studies in rat embryos, where elevated plasma concentrations of UAG and lower AG 
were demonstrated, with a circulating AG/UAG ratio that increased from fetal day 20 to 
postnatal days (Chanoine JP. Et al., 2004). A possible hypothesis is that UAG levels 
could be higher at birth, reflecting the fetal state, due to the immaturity of the GOAT 
system that turns UAG into the AG form. This enzyme has recently been discovered to 
be responsible for ghrelin octanoylation, but its physiological role and regulation is at 
present unclear, particularly in the fetal state and childhood. Furthermore, the placenta 
has been demonstrated to express very low levels of the GOAT transcript (Young J. et 
al., 2008, Gutierrez JA, 2008). Some authors have described the regulation of UAG 
and AG with respect to metabolic impairments in adulthood. Rodriguez et al. 
(Rodriguez A. et al., 2009) demonstrated that OB subjects with respect to lean 
individuals had increased levels of AG and decreased UAG. Barazzoni et al. 
(Barazzoni R. et al., 2007) demonstrated that AG/UAG ratio in patients with metabolic 
syndrome was increased and positively correlated with insulin resistance indexes 
compared with non-OB subjects. Pacifico et al. (Pacifico L. et al., 2009) showed lower 
UAG levels and higher AG/UAG ratio in patients with metabolic syndrome than in those 
without metabolic syndrome. Therefore, at present, the available information seems to 
suggest that pathological conditions may likely influence ghrelin form levels and their 
ratio. 
In the literature, acute AG administration in adult subjects induced a rapid increase in 
glucose and insulin levels with AG related to insulin resistance. On the contrary, UAG 
prevented AG effects when co-administered with AG and its levels have been found to 
be negatively associated with insulin levels and insulin resistance (Broglio F. et al., 
2004, Van der Lely AJ. Et al., 2009). Also in our study UAG levels and insulin showed a 
negative correlation, suggesting a major metabolic implication of UAG rather than AG 
in the neonatal period. Taking into account data in the literature together with our data, 
we can speculate that the peculiar state of ghrelin secretion in venous cord blood and 
the negative correlation between UAG and insulin levels, is focused to improve insulin 
sensitivity in the fetal state. Therefore, at birth, UAG could have a different role with 
respect to AG. Our data strengthens the importance of the different AG/UAG ratio, 
proposing a role in metabolic function and fetal growth. Accordingly, NN showed insulin 
levels similar to NW and lower than in OB children. Insulin levels primarily contribute to 
neonatal growth as insulin is one of its major hormone regulators promoting 
lipogenesis, glycogenesis, and protein synthesis (Fant ME & Weisoly D, 2001). 
There is a high degree of controversy regarding the relationship between ghrelin and 
anthropometric parameters. A negative association between UAG and birth weight has 
been demonstrated by Mendez-Ramirez et al. (Mendez-Ramırez F. et al., 2009) 
suggesting that diminished body weight induces different adaptive signals. A recent 
study by Martos-Moreno et al. (Martos-Moreno GA. Et al., 2009) assessing both 
preterm and term newborns, failed, like us, to demonstrate any association between 
AG and anthropometric indices, including ponderal index. Our study is in line with the 
majority of studies failing to find an association at birth, even if it has to be considered 
that our population includes only AGA NN. Moreover, both forms of ghrelin were 
independent of gender. The data in the literature are concordant with these results in 
NN (Martos-Moreno GA. Et al., 2009, Pirazzoli P. et al., 2005). The type of delivery 
does not influence ghrelin levels in our study nor in the literature (Bellone S. et al., 
2004, study 1, Mendez-Ramırez F. et al., 2009, Bellone S. et al., 2004). 
In conclusion, our study demonstrated that in physiological conditions, NN show higher 
UAG and lower AG levels compared with children in later life, resulting in a lower 
AG/UAG ratio. This hormonal pattern and the negative correlation between UAG and 
insulin levels would suggest a different metabolic function at birth. These peculiarities 
could be related to rapid hormonal and metabolic changes that could influence weight 
gain in early postnatal life. As such, it is important that further studies be performed to 
clarify the exact role of different ghrelin forms in fetal and postnatal life. 
2.3 Study 3 
 
Title 
Unacylated, acylated ghrelin and obestatin levels are differently 
inhibited by oral glucose load in pediatric obesity: Association with 
insulin sensitivity and metabolic alterations. 
 
 
Aim of the Study 
The first aim of this study was to detail post-OGTT AG, UAG and OBST dynamics in 
obese children and adolescents. A further aim was to explore if insulin resistance and 
metabolic alterations clustering in MS could be related to the fasting and glucose-
induced regulation of the three peptides. 
Subjects and Methods 
From November 2008 to December 2010, 30 prepubertal and 40 pubertal pediatric 
subjects with primary obesity and a body mass index (BMI) equal or higher than 97th 
percentile were consecutively enrolled. They were sedentary (engaging in less than 1 
or 2 h per week of mild physical activity at school). Obesity linked to genetic syndromes 
or organic dysfunctions like craniopharingiomas were excluded. Exclusion criteria also 
included the presence of type 1 and 2 diabetes, renal dysfunction, liver steatosis and 
other conditions known to influence body composition and energy balance (insulin and 
glucocorticoid treatments, endocrine diseases including sleep apnea syndrome). A 
group of 22 age-matched lean controls were also recruited. They engaged 6 h per 
week of moderate or vigorous physical activity. Physical activity was recorded by a 
register and was not instrumentally measured. All subjects regularly went to school and 
their socio-cultural environment was similar with a medium-high social extraction. 
Subjects underwent a complete clinical and auxological evaluation by a trainee 
research team using the Italian growth charts (Cacciari E. et al., 2006, Appendix 2). 
Auxological measurements on children have been described in study 1. Patients were 
divided into prepubertal (stage 1) and pubertal (stages 2e5) subjects. The waist-to-
height ratio was calculated by dividing waist circumference (cm) by height (cm) and 
used as another surrogate measure of central fat distribution. Systolic and diastolic 
blood pressure were measured three times on the left arm and after 15 min at rest in 
the supine position by using a standard mercury sphygmomanometer; the average was 
recorded and stratified according to pediatric percentiles of National High Blood 
Pressure Education Program Working Group on High Blood Pressure in Children and 
Adolescents (Pediatrics 2004, Appendix 4).  Children and adolescents underwent an 
evaluation of metabolic alterations clustering in MS by using the modified NCEP-ATP III 
criteria of Cruz and Goran (Cruz ML. & Goran MI., 2004, Appendix 5). Impaired fasting 
glucose and impaired glucose tolerance were defined according to MS and American 
Diabetes Association classifications. Accordingly, MS was defined by the presence of 3 
or more of the following 5 criteria: 1) waist circumference _ 90th percentile for age and 
gender; 2) triglycerides (TG) _ 90th percentile for age and gender; 3) HDLcholesterol _ 
10th percentile for age and gender; 4) impaired fasting glucose or glucose tolerance; 5) 
blood pressure _ 90th percentile for age and gender. Waist circumference percentiles 
were defined according to sex and age (McCarthy HD. et al., 2001, Appendix 3) 
Triglycerides and HDLcholesterol percentiles were considered in accordance to 
distribution based on American Academy of Pediatrics cut-off values (Daniels SR. et 
al., 2008). 
After a 12-h overnight fast, blood samples for AG, UAG, OBST, total cholesterol, HDL-
cholesterol, triglycerides, GH and IGF-I were measured. LDL-cholesterol was 
determined using the Friedwald formula. All subjects underwent an oral glucose 
tolerance test (OGTT, 1.75 g of glucose solution per kg, maximum 75 g). Blood 
samples were drawn for the determination of glucose and insulin every 30 min and of 
AG, UAG, OBST every 60 min from 00 to 1200 min. The energy intake and food 
requirements were defined for each subject starting from breakfast and ending at 
bedtime with direct questions to both children and parents and using validated food 
frequency questionnaires before performing tests. To assess food consumption, foods 
were divided according to the classic basic food groups of the Italian food pyramid 
elaborated by the Italian Institute of Research on Food and Nutrition. A balanced diet 
(50-60% of carbohydrates; 15-20% of proteins; 30% of total fats of which saturated less 
than 7%) was suggested in the two weeks before the study; the daily dietary intake was 
calculated mirroring that registered at the moment of recruitment to avoid weight and 
hormonal changes. The area under the curve (AUC) for parameters after OGTT was 
calculated according to the trapezoidal rule. The stimulus for insulin secretion related to 
the increment of plasma glucose as insulinogenic index was calculated as the change 
in insulin concentration from 0 to 30 min (Ins30) and from 0 to 120 min (Ins120). Insulin 
resistance was calculated using the formula of HOMA-IR = (fasting glucose x fasting 
insulin/22.5). Beta cell function at fasting was calculated using the formula of HOMAβ 
=(20 x fasting insulin)/(fasting glucose-3.5). Insulin sensitivity during OGTT was 
calculated from the Matsuda index. The disposition index, which reflects the capacity of 
pancreatic islets to compensate for lower insulin sensitivity, was defined as the product 
of the Matsuda Index and Ins 30 (DI30) or Ins120 (DI120) (De Fronzo RA. Et al., 2010). 
All beta-cell function measures yielded similar results. The study protocol was approved 
by the Local Ethical Committee and informed consent was obtained by all infant’s 
parents before the evaluations. 
Human AG and UAG (pg/ml) were measured by ELISA kits (BioVendor - Laboratori 
Medicina GmbH, Heidelberg Germany) AG: sensitivity: 0.2-0.6 pg/ml. Intra and inter-
assay coefficient of variation ranges: 11.8-13.2%. UAG: sensitivity 0.3-0.8 pg/ml. Intra 
and inter-assay coefficient of variation ranges: 10.3-10.9%. OBST (ng/ml) was 
measured by EIA kit (Peninsula Laboratories, LLC, CAF USA). Sensitivity: 0.02-25 
ng/ml. Insulin (mUI/ml; 1mUI/ ml = 7.175 pmol/l) was measured by chemiluminescent 
enzymelabelled immunometric assay (Diagnostic Products Corporation, Los Angeles, 
CA). Sensitivity: 2 mUI/ml. Intra- and inter-assay coefficient of variation: 2.5-8.3 and 
4.4-8.6%. Plasma glucose levels (mg/dl; 1 mg/dl:0,05551 mMol/liter) were measured by 
the gluco-oxidase colorimetric method (GLUCOFIX, by Menarini Diagnostici, Florence, 
Italy). Total cholesterol (mg/dl; 1 mg/dl: 0.0259 mMol/l), HDL-cholesterol (mg/dl; 1 
mg/dl: 0.0259 mMol/l), triglycerides (mg/dl; 1 mg/dl: 0.0113 mMol/l) were evaluated 
using standardized methods in the hospital’s chemistry laboratory. Total cholesterol 
concentration was measured by esterase and oxidase conversion (Advia 1650, Bayer 
Diagnostics, Newbury, UK); coefficient of variation 1.9%. Triglycerides and HDL-
cholesterol concentrations were measured by enzymatic determination (Advia 1650, 
Bayer Diagnostics, Newbury, UK); CV 1.7%. GH and IGF-I were measured with 
commercial kits. Categorical variables were expressed as frequencies or percentages. 
For continuous variables, non-Gaussian data were log transformed before analyses 
and all the data were expressed as absolute or delta mean ± SEM or percentiles to 
assist with interpretation. For continuous variables, the variation between groups was 
compared by means on nonparametric Wilcoxon and Manne -Whitney U tests. 
The stepwise regression model with two-tailed probability values and 95% confidence 
intervals was used to measure the strength of the association between variables. 
Statistical significance was assumed for p < 0.05. All statistical analyses were 




Clinical and biochemical fasting characteristics 
Seven prepubertal and 3 pubertal obese subjects were excluded because they were 
unable to complete the OGTT due to emotional issues. Complete anthropometrical and 
biochemical fasting data of the enclosed subjects are summarized in Table 6. 
 
Table 6. Clinical and biochemical characteristics of all subjects according to puberty. 
 
Of the obese subjects, 73.3% satisfied NCEP criteria. The most represented NCEP 
criteria, with the exclusion of waist circumference, were a systolic or diastolic blood 
pressure higher than the 90th percentile (93.3%) and HDL-cholesterol lower than the 
10th percentile (66.6%). The subjects were mainly euglycemic with only 18.3% (11/60) 
of them with dysglycemia. Lipid profile, percentiles of lipids and blood pressure, 
BMISDS and waist-to-height ratio were similar between prepubertal and pubertal 
individuals (Table 4). One normal weight control subject also satisfied NCEP criteria. 
MS. Subjects with metabolic alterations clustering in MS, including a normal weight 
individual, presented higher BMISDS and waist-to-height ratio (p < 0.001) (Table 7). 
 
Table 7. Metabolic syndrome (MS) criteria distribution and fasting and post-OGTT AG, 
UAG, OBST levels according to MS diagnosis. 
 
3.2. Hormonal parameters and OGTT study 
3.2.1. Glucose and insulin 
Both obese and control pubertal subjects presented higher fasting insulin levels (p < 
0.01) and insulin resistance measured as HOMA-IR (p < 0.01), but compensated with 
an increased beta-cell function defined with HOMA-β (p < 0.007). Ins120 and DI120 
were lower in controls than in obese subjects (p < 0.001). Glucose and insulin levels 
increased after OGTT (p < 0.0001). Glucose levels were similar between prepubertal 
and pubertal obese individuals while insulin at each time point and its AUC (9187.8 ± 
1148.9 vs 4927.7 ± 1152.9 mUI/ml*h; p < 0.04) were higher in pubertal subjects. 
Furthermore, insulin variation at 120 min was higher (67.5 ± 11.4 vs 44.9 ± 8.8 mUI/ml; 
p < 0.04) while Matsuda index (3.6 ± 0.5 vs 5.6 ± 1.2; p < 0.03) and DI30 (7.6 ±1.1 vs 
10.6 ± 1.9 mUI/mg*L_1; p < 0.05) were lower in pubertal individuals without variation in 
Ins30, Ins120 and DI120. The same patterns were observed in control subjects.  
MS. Obese subjects with metabolic alterations had higher insulin levels and insulin 
resistance (p < 0.0001) compensating with an increased beta-cell function (p < 0.0001). 
They also had a lower Matsuda index (4.2 ± 0.7 vs 5.1 ± 0.5; p < 0.01) and DI30 (8.2 
±1.1 vs 10.7 ± 1.6 mUI/mg*L-1; p < 0.04), higher insulin variation at 120 min (69.8 ± 9.4 
vs 29.3 ± 7.6 mUI/ml p < 0.04) and Ins120 (3.3 ± 0.5 vs 1.6 ± 0.4 mUI/mg*L-1; p < 0.02), 
but compensated with similar DI120.  
3.2.2. UAG 
Fasting UAG levels were higher in normal weight than obese subjects (p < 0.05) and 
lower in normal weight and obese pubertal than prepubertal subjects (p < 0.05), without 
gender differences. UAG decreased for the entire OGTT session (p < 0.0001) with a 
maximum inhibition at 60 min (-15.0 ± 1.5 pg/ml, p < 0.0001) (Figure 18). Pubertal 
obese subjects presented lower total UAG (DAUC: 1090.5 ± 171.0 vs 1363.3 ± 187.6 
pg/ml*h; p < 0.05) and lower inhibition of UAG concentrations at 60 min (-13.1 ± 2.1 vs 
-17.8 ± 2.2 pg/ml; p < 0.009), with respect to prepubertal individuals (Figure 18).  
The same dynamic was shown in control subjects. Normal weight children also 
presented a higher inhibition at 120 min with respect to the obese group (-15.6 ± 1.7 vs 
-11.1 ± 1.4 pg/ml; p < 0.04) (Figure 19). 
 
 
Figure 19. AG, UAG and OBST levels during OGTT in prepubertal and pubertal normal 
weight (white circle and dotted line) and obese (dark circle and solid line) subjects. 
 
When correcting the UAG variation at OGTT in control and obese subjects for puberty, 
sex. BMISDS, waist-to-height ratio, waist circumference or insulin sensitivity indexes, 
the models were not significant. HOMA-IR was the only predictor which explained the 
30.1% of the UAG variation (p < 0.01). Evaluating absolute values, AUC of UAG was 
negatively associated with insulin AUC and positively with Matsuda index (p < 0.04 for 
both). The Matsuda index explained with obesity the 46.1% of post-OGTT AUC of UAG 
(p < 0.04). GH and IGF-I levels did not correlate with UAG and did not influence each 
model. MS. 
Obese subjects with metabolic alterations that cluster in MS, had lower fasting UAG (p 
< 0.01) (Figure 20), but similar UAG dynamics after OGTT. However, UAG levels did 
not show a trend among metabolic components of MS. 
 
Figure 20. Fasting UAG levels in obese subjects with metabolic sybdrome (MS); black 





When correcting fasting UAG for MS diagnosis, puberty, sex, BMISDS, waist-to-height 
ratio, waist circumference and HOMA-β, the models were not significant. However, 
when correcting for MS, puberty, sex and HOMA-IR, the Matsuda index or fasting 
insulin UAG levels remained lower (5.5-0.67 fold), but the predictors were only indices 
of insulin resistance and not MS. The model did not change if all subjects or exclusively 
obese subjects were included. 
3.2.3. AG 
Fasting AG levels were higher in normal weight than obese subjects (p < 0.05), with 
lower levels in obese pubertal than in prepubertal subjects (p < 0.05), without gender 
differences. AG/UAG tended to be higher in obese children without reaching 
significance. AG levels decreased at 60 min after OGTT (-1.6 ± 0.4 pg/ml, p < 0.001; 
and -1.7 ± 1.2 pg/ml, p < 0.05) and subsequently increased at 120 (-0.2 ± 0.5 pg/ml; p < 
0.0001 and 0.2 ± 1.7 pg/ml; p < 0.01) returning to basal concentrations in both obese 
and control subjects (Figure 19). The AG dynamic was similar in prepubertal and 
pubertal subjects. 
Correlation analyses revealed that the AG variation, particularly at 60 min, and the AG 
nadir were associated with the waist-to height ratio (r: 0.384; p < 0.004) and Ins120 (r: -
0.245; p < 0.01), which were maintained when correcting for puberty and BMISDS. 
Regression analyses performed with significant factors and adjusted for sex, puberty 
and BMISDS, revealed that waist-to height ratio explained 34.4% of the AG variation at 
OGTT (p < 0.005). AG secretion associated with insulin only when evaluated as an 
absolute value, including the effect of fasting concentration in all subjects or exclusively 
obese subjects. Accordingly, the AUC of AG was explained for 49.5% positively by 
Ins120 and negatively by insulin AUC (p < 0.001) in adjusted models. GH and IGF-I 
levels did not correlate with AG and did not influence each model. 
MS. Subjects with and without metabolic alterations had similar fasting and post-OGTT 
AG levels with no trends observed among the components. 
3.2.4. OBST 
Fasting OBST levels were higher in obese than in controls with lower levels in obese 
pubertal than prepubertal subjects (p < 0.05). OBST decreased for the entire OGTT 
session (p < 0.01) with maximum inhibition at 120 min in both obese and control 
subjects (-0.236 ± 0.107 ng/ml, p < 0.0001; and -0.133 ± 0.076 ng/ml; p < 0.01) (Figure 
19) and no differences with respect to puberty. Correlation analyses revealed that the 
OBST variation at 120 min and OBST nadir were associated with absolute and delta 
glucose variation at 120 min after OGTT (r:0.379; p < 0.006) in obese children, without 
being modified by sex or puberty. Evaluating absolute values, AUC of OBST was 
associated with glucose variations at 120 min (r:-0.332; p < 0.006), AUC of glucose (r:-
0.438; p < 0.0001) and Ins120 (r:-0.376; p < 0.002) in all subjects. The AUC of glucose 
and Ins120 explained 55.1% of the AUC of OBST (p < 0.0001) in adjusted models. GH 
and IGF-I levels did not correlate with OBST and did not influence each model. 
MS. Subjects satisfying NCEP criteria had a lower inhibition of OBST at 60 min (-0.061 
±0.040 vs -0.586 ± 0.272 ng/ml p < 0.05) (Figure 21). Fasting OBST levels did not 
show a trend among components of MS.  
 
 
Figure 21. Variation of Obestatin levels respect to basal at 60 min post-OGTT in 
subjects with metabolic syndrome (MS; black bar) and whitout metabolic syndrome 




In a model composed by all metabolic alterations and controlled by puberty and sex, 
46.7% of the OBST variation at 60 min in obese subjects was explained by HDL-
cholesterol being lower than the 10th percentile and blood pressure higher than 90th 
percentile (p < 0.0001). Alternatively, 26.4% of the OBST variation was explained by 
HDL-cholesterol being lower than 10th percentile in the entire group (p < 0.0001). 
Including the insulin variation at 120 min and Ins120 to the model, the best predictors 
were Ins120 and HDL-cholesterol which explained 59.9% of the OBST variation (p < 
0.0001) for obese, but not for normal weight subjects (Table 8). 
 
 
Table 8. Relative variation of Obestatin at 60 min (Δ60OBST) during OGTT during the 




Previous studies have evaluated the total ghrelin response to OGTT both in adulthood 
(Wiedmer P. et al., 2007, Barber TM. Et al., 2008, Prodam F. et al., 2008) and in 
childhood (Baldelli R. et al., 2006, Paik KH. Et al., 2006, Lanyi E. et al., 2007) showing 
an inhibition. However, this is the first study aiming to investigate the contemporary 
dynamics of AG, UAG and OBST after OGTT administration in pediatric obesity with 
respect to insulin resistance, indices of beta-cell function and metabolic alterations that 
cluster in MS. The results of the present study show that UAG, AG and OBST are all 
inhibited by glucose load but with particular patterns and each associated with different 
factors. Specifically, post-OGTT UAG levels are associated with insulin sensitivity, 
while conversely, AG associates with compensatory insulin secretion and the 
insulinogenic index. OBST is associated with glucose and compensatory insulin 
secretion. Metabolic alterations that cluster with MS are not associated with UAG and 
AG, whereas HDL-cholesterol correlates with glucose-induced OBST secretion. 
It has yet to be demonstrated that measuring total ghrelin levels has limited value. Only 
a few studies have reported AG and UAG levels in pediatric subjects and they are 
mainly focused on adolescents (Harada T. et al., 2008, Lanyi E. et al., 2007, Mackelvie 
KJ. et al. 2007). Interestingly, the peptides are modulated by puberty at fasting with 
decreasing levels associated with insulin resistance according to data evaluating total 
ghrelin secretion (Van der Lely AJ. Et al., 2004, Wiedmer P. et al., 2007, Bacha F. et 
al., 2005). 
Puberty does not seem to associate with a different glucose- induced response, with 
the exception of UAG. However, these data need to be confirmed in larger populations 
that allow an evaluation according to the individual Tanner stages. 
4.1. UAG 
The fasting UAG concentration was lower in children and adolescent obese and in 
those with a cluster of MS components. This inhibition was mainly influenced by the 
insulin resistance state and not by the components of MS. Being that UAG is the major 
circulating form (Van der Lely AJ. Et al., 2004, Wiedmer P. et al., 2007), these results 
are supported by all studies evaluating total ghrelin levels which repeatedly confirmed a 
lower fasting concentration in conditions of insulin resistance (Van der Lely AJ. Et al., 
2004, Wiedmer P. et al., 2007, Barber TM. Et al., 2008, Langenberg C. et al., 2005). 
However, after OGTT UAG concentrations were further inhibited in the prepubertal 
state and in normal weight subjects being dependent on insulin sensitivity. The lower 
UAG suppression in pubertal and obese subjects with respect to prepubertal and 
normal weight subjects, occurs independently of weight or fat distribution and indirect 
measures of adiposity confirming that insulin is a key factor in the regulation of UAG 
secretion. Evaluation of insulin resistance across Tanner stages will be helpful in 
getting a clearer picture. A lower fall in UAG secretion may influence the regulation of 
insulin secretion over time, although this remains to be elucidated in longitudinal 
studies. 
4.2. AG 
In this study fasting AG secretion was lower in obese subjects and presented a similar 
inhibition at 60 min post-OGTT in both obese and control children being followed by a 
rebound to basal levels. These data confirm those of another two studies conducted in 
smaller groups (Paik KH. et al., 2006, Lanyi E. et al., 2007) However, Lanyi and co-
workers observed that AG levels rapidly surged at 120 min in obese adolescents, but 
not controls, suggesting that the relative increase of AG in obese children at 120 min 
after OGTT might induce early hunger and contribute to the maintenance of obesity 
(Lanyi E. et al., 2007). In contrast, we evaluated total absolute AG levels, which 
included the effects of fasting and rebound values, as well as delta post-OGTT AG 
secretion. All data correlated with insulin, in agreement with other authors (Park WH. et 
al., 2007), as well as the insulinogenic index at 1200 min. These data suggest that 
insulin has a major role also in the AG glucose-induced regulation. The role of insulin is 
in agreement with the lower levels in pubertal individuals. The association with the 
insulinogenic index at 1200 , which expresses a late compensatory insulin secretion to 
glucose, suggests an interplay between the precocious surge of AG, insulinand 
glucose. Whether a progressive decrease in insulin secretion allows AG levels to 
rebound or the increase in AG concentrations inhibits the later glucose-induced insulin 
secretion, demonstrated by an AG inhibitory action on the first phase of insulin 
secretion (Wiedmer P. et al., 2007, Dezaky K. et al., 2008, Broglio F. et al., 2008) and 
an inhibition of insulin on ghrelin (Van der Lely AJ. Et al., 2004, Wiedmer P. et al., 
2007, Barber TM. Et al., 2008, Purnell JQ. Et al., 2003) cannot be explained in a cross-
sectional study but it requires interventional models. 
4.3. OBST 
Fasting OBST levels were higher in obese than normal weight subjects in this study. 
OBST regulation in obesity is still a matter of debate with higher (21,22 Vicennati V. et 
al., 2007, Reinehr T. et al., 2008) lower (Guo ZF. Et al., 2007, Anderwald-Stadler M. et 
al., 2007, Balagopal PB. Et al., 2010) or unchanged levels (Zou CC. et al., 2009) in 
both children and adults. Based on available data, it is difficult to explain these 
disparate findings which seem mainly to depend on values in the obese groups, age 
and ethnicities. Candidate regulators to explain these debatable data include several 
parameters of glucose and lipid metabolism. Our results also demonstrated that 
glucose induced OBST inhibition is blunted in subjects with metabolic alterations 
clustering in MS. Firstly lower HDL-cholesterol and secondly higher blood pressure 
levels are the major contributors more of a presence of the MS cluster. HDL-cholesterol 
may seem an unlikely variable associated with ghrelinergic system, however many 
studies have confirmed these findings for both plasma ghrelin concentrations (Purnell 
JQ. Et al., 2003, Langenberg C. et al., 2005) and ghrelin gene polymorphisms (Choi 
HJ. Et al., 2006). 
Moreover, HDL-cholesterol transports both AG and mainly UAG through its N- and C-
terminal sequence (Holmes E. et al., 2009). The possibility of OBST bound to 
lipoproteins has not been investigated and should be further clarified. The association 
between OBST dynamics and blood pressure is in line with similar preliminary results at 
fasting in humans and needs further investigation to elucidate its physiological 
significance (Tang SQ. et al., 2008, Anderwald-Stadler M. et al., 2007). It cannot be 
excluded that different findings for OBST levels in the published papers on obesity are 
mainly due to the uninvestigated HDL-cholesterol or blood pressure levels. However, 
after OGTT, OBST reached a nadir at 120 min with a progressive and delayed 
inhibition in both normal weight and obese children. Interestingly, higher glucose levels 
at the end of the testing session and, a higher insulinogenic index are both associated 
with a blunted inhibition of this peptide in all the groups. These results are in agreement 
with a previous observation in adults that OBST levels are reduced in insulin-resistant 
subjects at fasting but are refractory to inhibition in the same individuals during 
hyperinsulinemic euglycemic clamp with respect to those that are insulin-sensitive.20 
On this basis, insulin and mainly whole body insulin sensitivity, as expressed by the 
insulinogenic index, seem to be regulators of the OBST secretion. Whether an excess 
of insulin may be responsible for increased OBST levels in obesity still remains 
unknown. 
4.4. Limitations 
Our study has a few potential limitations. First, it was a crosssectional study thus the 
data needs to be confirmed in a longitudinal study. Second, AG is not so stable and 
degradation can occur. So, unless the stability of AG in the samples is preserved, it 
may not represent the physiological regulation. However, fluctuations and dynamics 
remain a good representation as the bias should be the same at each time point. Third, 
pubertal stagewas divided only into prepubertal and pubertal and not the five stages of 
Tanner because a significant sample size could not be reached for each stage. 
Despite the fact that all stages were included, minimal changes among each of these 
cannot be excluded, in particular regarding OBST regulation. Future investigations 
considering the Tanner stages could better explain the role of insulin resistance in the 
system. Fourth, physical activity was recorded by a register and was not instrumentally 
measured. Because, control subjects performed 6 h per week of moderate or vigorous 
physical activity while obese children engaged in less than 2 h of mild physical activity 
in school hours, a role of physical activity in the regulation of the system cannot be 
excluded, considering the data on acute exercise on the system (Mackelvie KJ. et al. 
2007). 
5. Conclusions 
In conclusion, the present study demonstrates that UAG, AG and OBST have different 
glucose-induced dynamic patterns in obese pediatric subjects. Compensatory 
increases in insulin secretion pointing to insulin resistance and indices of insulin 
sensitivity are the major contributors associated with the system. Metabolic alterations, 
mainly HDL-cholesterol, are associated with the OBST secretion. Further investigations 
to be performed will explain whether these secretory profiles could be features of 
adulthood, as well as their physiological significance. 
 2.4 Study 4 
 
Title 
High-end normal adrenocorticotropic hormone and cortisol levels are 
associated with specific cardiovascular risk factors in pediatric 
obesity: a cross-sectional study 
 
 
Aim of the Study 
This study recruited a large cohort of overweight and obese pediatric subjects to 
determine the following: 
1.  to establish whether an association between cardiovascular risk factors and 
morning cortisol levels is present in obese Caucasian children and adolescents; 
2. to evaluate whether ACTH is associated with cardiovascular risk factors in this 
population; and 
3. to establish whether ACTH and cortisol levels are higher in those with specific 
cardiovascular risk factors. 
Subjects and Methods 
 
Study design and population 
This was a cross-sectional study. We consecutively recruited 450 children and 
adolescents, aged 4 to 18 years, referred to the Pediatric Endocrine Service of our 
Hospital from January 2008 to October 2011 for obesity. The Hospital covers an area 
of North-East Piedmont with a population of approximately 500,000. The sampling rate 
was based on the age structure of the community and of the general pediatric 
population referred to the Service. Subjects were eligible if they were generally healthy, 
overweight or obese and not on a weight-loss diet (no engagement in any program to 
lose weight before the enrollment). Exclusion criteria were the known presence of 
diabetes or high blood pressure (BP), the use of drugs which influence glucose or lipid 
metabolism, specific causes of endocrine or genetic obesity, low birth weight, distress 
during blood sampling or a difficult phlebotomy (more than 5 minutes). The protocol 
was conducted in accordance with the declaration of Helsinki and was approved by the 
Local Inter-Hospital Ethic Committee (Maggiore Hospital Ethical Committee). Informed 
consent was obtained from all parents prior to the evaluations after careful explanations 
were given to each patient. 
Anthropometric and biochemical measurements. 
All subjects underwent a clinical evaluation by a trained research team. Pubertal stages 
were determined by physical examination, using the criteria of Marshall and Tanner 
(Appendix 1). 
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer, and body 
weight with light clothing to the nearest 0.1 kg using a manual weighing scale. Body 
mass index (BMI) was calculated as body weight divided by squared height (kg/m2). 
The BMI standard deviation score (BMISDS) was calculated by the least median 
squares method (Appendix 7).  
Waist circumference was measured at the high point of the iliac crest around the 
abdomen and was recorded to the nearest 0.1 cm. 
Systolic BP (SBP) and diastolic BP (DBP) were measured three times at 2-minute 
intervals using a mercury sphygmomanometer with an appropriate cuff size after 
participants were seated quietly for at least 15 minutes, with their right arm supported 
at the level of the heart and feet flat on the floor, prior to other physical evaluations, and 
at least 30 minutes after blood sampling, using a standard mercury 
sphygmomanometer. Mean values were used for the analyses. Hypertension was 
determined if BP values recorded on enrollment day and on blood samples day are 
always elevated. 
After a 12-hour overnight fast, children arrived at the clinical center at 7.30 AM and 
rested comfortably for half an hour prior to blood testing. At 8.00 AM, blood samples 
were taken for measurement of ACTH, cortisol, glucose, insulin, high-density 
lipoprotein (HDL)-cholesterol and triglycerides. ACTH and cortisol samples were drawn 
first. 
Subjects also underwent an oral glucose tolerance test (OGTT; 1.75 g of glucose 
solution per kg, maximum 75 g). Plasma samples were immediately separated and 
stored at-80°C. Children were screened for symptoms suggestive of Cushing’s 
syndrome, and a 1 mg overnight dexamethasone suppression test and urinary free 
cortisol measurement were performed in case of suspicion. Signs of Cushing’s 
syndrome were a low height percentile and high weight percentile as suggested by the 
guidelines of the Endocrine Society (Nieman LK et al., 2008). We also screened 
children for a height below that expected from parental height or a previous episode of 
severe hypertension. Children with positive screenings were excluded. 
Insulin resistance was calculated using the homoeostasis model assessment of insulin 
resistance (HOMA-IR). Low-density lipoprotein (LDL)-cholesterol was calculated by the 
Friedwald formula. ACTH and cortisol levels were measured by an Immulite 2000 
Medical System (Medical Systems S.p.A., Via Rio Torbido 40, Genova, Italy) 
(sensitivity: <12.0 pmol/l and <27.59 nmol/l, respectively). Other assays and formulas 
are as previously described in study 3. 
Definitions 
Subjects were classified as overweight (BMI: 75th to 94th percentile) or obese (BMI: 
≥95th percentile) according to Italian growth charts (Cacciari E. et al., 2006, Appendix 
2). Children and adolescents underwent an evaluation for cardiovascular risk factors 
identified in the classification of MetS and by using cutoff values of the modified 
National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III criteria 
as follows: (1) triglycerides ≥90th percentile for age and sex; (2) HDL-cholesterol ≤10th 
percentile for age and sex; and (3) impaired fasting glucose or glucose tolerance. High 
LDL-cholesterol was defined as ≥90th percentile for age and sex. Because of 
differences in the literature, hypertension was defined according to two specific cut-offs: 
(1) >95th percentile as suggested by the National High Blood Pressure Education 
Program (NHBPEP) Working Group of American Academy of Pediatrics (AAP) 
(Pediatrics 2004, Appendix 4); and (2) >90th percentile as suggested by definitions of 
pediatric MetS (Cruz ML. & Goran MI., 2004, Cook S. et al., 2003, De Feranti SD., 
2004). Triglyceride, LDL-cholesterol and HDL-cholesterol cut-off levels for age and sex 
were those used in the Lipid Research Clinic Pediatric Prevalence Study (Daniels SR. 
et al., 2008). Impaired fasting glucose and impaired glucose tolerance were defined 
according to MetS and American Diabetes Association classifications as fasting plasma 
glucose of ≥5.6 to 6.9 nmol/l, and as 2-h post-OGTT glucose of ≥7.8 to 11.0 nmol/l, 
respectively (Cruz ML. & Goran MI., 2004, Appendix 6). Both SBP and DBP values 
were stratified according to percentiles of the NHBPEP Working Group (Daniels SR. et 
al., 2008).  
Statistical analysis 
All data are expressed as mean ± standard deviation (SD), absolute values or 
percentages. A sample of 84 individuals has been estimated to be sufficient to 
demonstrate a difference of 27.59 μg/dl in cortisol with a SD of 2 with 90% power and a 
significance level of 95% using the Student’s t test. Distributions of continuous 
variables were examined for skewness and were logarithmically transformed as 
appropriate. Correlation of ACTH and cortisol with continuous values of SBP, DBP, 
triglycerides, HDL-cholesterol and LDL-cholesterol, glucose, insulin, and HOMA-IR 
were examined using Pearson correlation coefficients. Partial correlation was used to 
correct for covariates. Analysis of covariance was used to determine differences in 
subjects with and without cardiovascular risk factors. Covariates were sex, age, 
pubertal stage, and BMI; BMISDS was used when the analysis was not contemporarily 
corrected for age. Analysis of covariance was also used to determine ACTH and 
cortisol differences among age and pubertal subgroups, with BMISDS (or BMI), HOMA-
IR and sex as covariates. 
ACTH and cortisol were also categorized into tertiles. Multiple logistic regression was 
used to determine the association of tertiles of ACTH and cortisol with the odds ratio 
(OR, 95% CI) of each cardiovascular risk factor. 
Tertiles of ACTH and cortisol were included as independent variables, with the first 
tertile as the reference group. Statistical significance was assumed at P <0.05. The 
statistical analysis was performed with SPSS for Windows V.17.0 (SPSS Inc., Chicago, 
IL, USA). 
Results 
Anthropometric and metabolic phenotypes of all groups. 
The final dataset included 406 participants, aged 4 to 18 years (198 male, 208 female). 
A total of 29 subjects were excluded because they did not satisfy inclusion criteria (15 
with difficult blood sampling, 5 with a low birth weight, 4 with hypothyroidism in 
thyroiditis, and 5 treated with glucocorticoids in the last 6 months). Other exclusions 
were two subjects diagnosed with late-onset congenital adrenal hyperplasia, eight with 
distress during BP monitoring, and five who refused the dexamethasone test. A total of 
31 out of 406 subjects had the dexamethasone test and showed correct inhibition of 
cortisol levels (all <27.59 μg/dl), so Cushing’s syndrome was excluded. We performed 
24-h urine sampling for free cortisol measurement, but this was incomplete in 20 out of 
31 patients. 
ACTH levels were higher in Tanner 4 to 5 stage participants (P <0.001) and in 14.0 to 
15.9-year-olds (P <0.01) in males than in females, and this was also the case in the 
analysis corrected for BMISDS (or BMI) and HOMA-IR (Figure 23). 
Cortisol levels were higher in Tanner 4 to 5 stage participants than in Tanner 1 stage 
participants for the whole group (P <0.02), and in females (P <0.02); this was also the 







Figure 23. Tanner dependent (A) and age dependent (B) adrenocoticotropic hormone 
ACTH (pmol/l) and cortisol (nm/l) levels in 406 overweight and obese children and 




A total of 97 (24.0%) subjects were overweight and 309 (76.0%) were obese. 
Of the 406 subjects included, 23 (5.7%) had impaired fasting glucose, 10 (2.5%) had 
impaired glucose tolerance and 5 (1.2%) had both. None were diabetic. A total of 91 
(22.4%) subjects had triglycerides ≥90th percentile, 216 (53.2%) had HDL-cholesterol 
≤10th percentile and 25 (6.2%) had LDL-cholesterol ≥90th percentile for age and sex. 
Hypertension according to NCEP-ATP criteria was diagnosed in 339 (83.4%) subjects 
and in 274 (67.4%), according to AAP criteria. Only 1 subject presented with all 
cardiovascular risk factors, while 63 (15.5%) had none. 


















Table 9. Biochemical and clinical characteristics of subjects. 




Associations between ACTH, cortisol and metabolic parameters. 
In the unadjusted analyses, ACTH and cortisol levels were positively associated with 
SBP, DBP, triglycerides, fasting glucose and HOMA-IR. ACTH, but not cortisol, was 
positively associated with a higher BMI and insulin levels. Cortisol, but not ACTH, was 
positively associated with LDL-cholesterol levels (Table 3). Adjustment for confounding 
factors did not change any association for ACTH and revealed a further association 
with 2-h post-OGTT glucose. However, the association between cortisol and HOMA-IR 
was lost after adjustment (Table11). 
 
Table 11. Partial correlation for adrenocorticotropic hormone (ACTH pmol/l) and 
cortisol (nmol/l) with cardiovascular risk factors. 
 
ACTH and cortisol levels and cardiovascular risk factors. 
In the unadjusted analyses, ACTH levels were higher in those with triglycerides ≥90th 
percentile (P <0.003) and LDL-cholesterol ≥90th percentile (P <0.04). Higher ACTH 
levels were also observed in those with impaired fasting glucose or glucose tolerance 
(P <0.001) and BP ≥95th percentile (P <0.009), but not in those with HDL-cholesterol 
≤10th percentile and BP ≥90th percentile. Cortisol levels were higher in individuals with 
LDL-cholesterol ≥90th percentile (P <0.006) and BP ≥95th percentile (P <0.02). 
In adjusted models, ACTH levels remained higher in those with triglycerides ≥90th 
percentile (P <0.02) and impaired fasting glucose or glucose tolerance (P <0.001). 
Cortisol levels remained high in those with BP ≥95th percentile and LDL-cholesterol 
≥90th percentile. Higher ACTH levels (third tertile >5.92 pmol/l), although within the 
normal range, increased the odds of hypertension (>95th percentile), higher 
triglycerides, impaired fasting or post-OGTT glucose tolerance in the univariate 
analysis. After adjusting for confounding factors, only the odds of higher triglycerides 
(OR 2.118, 95% CI 1.139 to 3.939), impaired fasting or post-OGTT glucose (OR 2.548, 
95% CI 1.003 to 6.475) remained significant. Higher cortisol levels (third tertile, >383.5 
nmol/l), although within the normal range, increased the odds of hypertension (>95th 
percentile; OR 1.593, 95% CI 1.002 to 3.133) and higher LDL-cholesterol (OR 3.546, 







Table 12. Plasma adrenocorticotropic hormone (ACTH pmol/l) and cortisol (nmol/l) 




A series of studies in adults and a few studies in selected groups of adolescents, have 
shown alterations in cortisol in individuals with cardiovascular risk factors (Anagnostis 
P. et al. 2009, Reinehr T. et al. 2004, Barat P. et al., 2007). In adults, abdominal 
obesity, high triglyceride and low HDL-cholesterol levels, hypertension, hyperglycemia, 
MetS and chronic stress have all been characterized by hyperactivity of the HPA axis 
leading to a functional hypercortisolism. It has also been suggested that inhibiting 
cortisol action could provide a novel approach for these conditions (Anagnostis P. et al. 
2009). 
In the present study, although ACTH and cortisol levels were within the normal ranges, 
we observed higher ACTH and cortisol levels in obese children and adolescents with 
specific cardiovascular risk factors. In particular, ACTH levels were higher in those with 
higher glucose and triglyceride levels, while cortisol levels were higher in those with 
hypertension and higher LDL-cholesterol, thereby increasing the risk for these 
metabolic disturbances. The first aim of our study was to determine whether cortisol 
and ACTH were associated with cardiovascular risk factors in obese Caucasian 
children and adolescents. 
We showed that ACTH and cortisol were directly associated with glucose, triglycerides, 
and BP independently of sex, age, puberty, BMI and insulin resistance. Moreover, 
cortisol was also associated with LDL-cholesterol. These data suggest that the link 
between HPA and comorbidities in obesity is present in very young children and that 
elevated ACTH and cortisol levels, although within normal ranges, are already 
associated with cardiovascular risk factors. The data regarding cortisol are in 
agreement with the study of Weigensberg and coworkers who demonstrated that 
cortisol is higher in obese Latino youths with MetS, independent of the degree of 
obesity and insulin sensitivity (Weigensber MJ. Et al., 2008). Many studies evaluating 
cortisol in pediatric obesity have demonstrated an association between cortisol and 
insulin resistance, leading to hypothesis that a relationship between cortisol and 
metabolic disturbances would be mediated by insulin sensitivity (Reinehr T. et al. 2004, 
Adam TC. Et al., 2012, Barat P. et al., 2007). However, both our data and those from 
Latino youths suggest that the relationship is complex and not only due to insulin 
resistance. It is well known that Hispanic people have a higher prevalence of type 2 
diabetes and cardiovascular diseases (CooK S. et al., 2003, Weiss R. et al., 2004, 
Duncan GE. Et al., 2004, Tfayli H. et al., 2009), thus such a selected sample of 
subjects could have quite a different phenotype linked to their genetic susceptibility. 
Despite this, however, our data and that of others have shown that the association with 
cardiovascular risk factors remains positive in non-specific populations of obese 
children and adolescents (Reinehr T. et al. 2004, Barat P. et al., 2007). The lack of 
association between BMI and cortisol was unexpected, particularly because an 
association was present for ACTH. However, a number of studies have failed to show 
an association (Weigensber MJ. Et al., 2008, Pasquali R. et al., 2000, Rosmond R 
1998, Knutsson U. et al., 1998). Similar to the lack of an association between BMI and 
plasma cortisol in the obese population, a lack of association between BMI or body fat 
levels and urinary free cortisol and free cortisone (in 24-h urine) has also been 
demonstrated in non-obese children (Dimitriou T. et al., 2003). One explanation could 
be the homogenous population in terms of weight in our and other studies. However, it 
could be that ACTH is a better biomarker in childhood in relation to obesity and 
associated cardiovascular risk factors. Accordingly, major glucocorticoid metabolites in 
24-h urine samples (reflecting ACTH-driven adrenocortical activity or cortisol secretion) 
were significantly associated with body fat in non-obese children (Dimitriou T. et al., 
2003). The latter findings, together with our cross-sectional study, suggest that 
adrenocortical activity (driven by ACTH) is related to body composition during growth 
whether children are lean/normal weight (Dimitriou T. et al., 2003) or obese. However, 
in this context it is important that higher body fat levels do not always imply higher total 
blood cortisol although ACTH is increased. ACTH can be increased and total circulating 
cortisol concomitantly reduced (Jessop DS. Et al., 2003). However, also in children 
reduced cortisol blood levels are not uncommon in case of elevated body fat levels 
(Chalew SA. Et al., 1991, Soros A. et al., 2008). Moreover, our paper and that of 
Reinehr and Andler (Reinehr T. et al. 2004) indicate that children’s total cortisol plasma 
levels are not necessarily reduced if body fat is higher. However, really elevated cortisol 
concentrations in obese children appear to emerge only if a marked insulin resistance 
is also present (Reinehr T. et al. 2004). Interestingly, we also observed changes in 
ACTH and cortisol levels at the last years and at the end of puberty. Healthy adults 
have higher blood cortisol levels than children. Adults also have clearly higher 24-h 
excretion rates of free cortisol and free cortisone after correction for body surface area 
than children. However 24-h excretion of free cortisol and free cortisone in healthy 
children up to an age of about 14 years is constant after body surface area correction 
(Dimitriou T. et al., 2003, Wudy SA. Et al., 2007). We showed in our obese cohort that 
cortisol rose in Tanner 4 to 5 stage participants, particularly in females. Conversely, 
ACTH was higher in males with respect to females in the same pubertal stage and at 
the age of 14.0 to 15.9 years in presence of still unmodified cortisol levels. These data, 
with respect to what age ACTH and cortisol start to increase, have to be considered in 
future works on cortisol in obese adolescents. We also demonstrated that ACTH levels 
were associated with metabolic alterations in pediatric obesity, and that some 
associations were stronger with respect to those of cortisol, in particular insulin 
resistance. The characteristics of this association suggest that higher ACTH levels 
could better reflect the interplay between obesity and the HPA axis, and that cortisol-
binding globulin (CBG) may be important. Higher CBG levels reduce the rate of cortisol 
clearance, and thus reflect cortisol levels in plasma (Gagliardi L. et al., 2010). In a large 
population study, CBG levels were negatively correlated with BMI, BP and insulin 
resistance, perhaps indicating suppression of CBG synthesis, or a CBG gene 
polymorphism in obesity (Fernandez-Real JM. Et al., 2002). Since stress-induced 
cortisol pulses are elevated in obesity, lower CBG levels may enhance the 
glucocorticoid action on tissues and also increase the cortisol clearance. Because CBG 
is costained with ACTH in corticotrophs and is colocalized with vasopressin in the 
hypothalamus (Gagliardi L. et al., 2010), lower CBG levels may result in higher ACTH 
levels in obesity by regulating the HPA stress response. However, ACTH levels also 
represent expression of the negative feedback loop formed by corticotropin-releasing 
hormone and cortisol, which is influenced by genetic differences in the glucocorticoid 
receptor (Witchel SF. Et al. 2006). The highest tertiles of the normal ranges of ACTH 
and cortisol levels in this study were associated with an increased risk of higher 
triglyceride and LDL-cholesterol levels, respectively. The specific associations for 
ACTH and cortisol were of interest. The association between cortisol and LDL-
cholesterol could be a consequence of multifactorial mechanisms, including direct and 
indirect effects on lipolysis, free fatty acid production and turnover, and very-low-density 
lipoprotein synthesis and fatty acid accumulation in the liver (Anagnostis P. et al. 2009, 
Arnaldi G. et al., 2010). The association between ACTH and triglycerides may be 
secondary to the strong association between ACTH and insulin resistance in our study. 
Moreover, ACTH has been shown to increase apolipoprotein E levels in humans, a key 
protein in determining triglyceride metabolism (Berg AL. et al., 2006). However, a 
higher ACTH-driven adrenocortical activity could have consequences for the hepatic fat 
and triglyceride metabolism likely through a higher hepatic glucocorticoid metabolism 
(Anagnostis P. et al. 2009, Arnaldi G. et al., 2010). Higher ACTH levels, although within 
the normal range, were also associated with fasting and post-challenge glucose, and 
ACTH levels were strong predictors of hyperglycemia. These data are in line with 
findings in obese Latino youths (Adam TC. Et al., 2012, Weigensber MJ. Et al., 2008), 
suggesting that changes in the HPA in altered glucose conditions are present also in a 
broader population. The relationship between glucose and cortisol is in line with 
glucocorticoid effects on hepatic gluconeogenesis, insulin secretion and resistance 
(Anagnostis P. et al. 2009, Lambillotte C. et al., 1997). However, only ACTH increased 
the risk of high glucose levels. These findings are concordant with the evidence that 
lower daily cortisol levels and normal CBG concentrations have been shown in 
childhood obesity as an age-dependent mechanism to prevent type 2 diabetes (Soros 
A. et al., 2008). Because ACTH-driven adrenocortical activity or cortisol secretion has 
been shown associated with body fat in childhood, as previously discussed (Dimitriou 
T. et al., 2003), ACTH might also associate with higher glucose levels before overt 
disease. In agreement with this hypothesis is that none of the subjects in the present 
study had overt type 2 diabetes, but they had impaired fasting glucose or glucose 
tolerance. We also found higher cortisol levels, although within the normal range, in 
subjects with higher BP, reflecting the data in Latino youths (Weigensber MJ. Et al., 
2008). It is interesting to note that when a cut-off was imposed, cortisol levels were 
significantly higher only with respect to the 95th percentile of BP, whereas there was no 
significant association with the 90th percentile, which is suggested as pathological in 
the MetS definition (Cruz ML. et al., 2004), and is prehypertensive according to the 
NHBPEP Working Group definition (Pediatrics 2004). The lack of an association 
between cortisol and hypertension using the lower BP cut-off suggests that cortisol 
levels may be increased only in overt disease. HPA alterations are thus likely to be a 
consequence of obesity comorbidities, as is also suggested by normalization of cortisol 
levels after weight reduction (Reinehr T. et al. 2004). 
There are limitations in the present study. First is the cross-sectional design, in which 
we could not determine whether slightly higher ACTH and cortisol levels were a 
consequence rather than a cause of cardiovascular risk factors in pediatric obesity. 
Longitudinal studies might clarify this aspect. The second limitation was the inability to 
define the length of exposure to HPA alterations. The third limitation was evaluation of 
the HPA without the evaluation of urinary free cortisol. It is difficult to collect daily urine 
samples properly in pediatric cases, in particular in younger children. In fact, urinary 
samples were incomplete in most of the children who also took the dexamethasone test 
for exclusion of Cushing syndrome. However, a single morning fasting cortisol 
measurement has been shown to be associated with chronic stress and metabolic 
disturbances (Pervanidou P. et al., 2012). The fourth limitation was the lack of precise 
data on socioeconomic status due to the refusal of many parents. Socioeconomic 
status has been found to affect chronic stress and cortisol levels and its role needs to 
be explored further. The fifth limitation was the absence of true body fat measurements 
through radiological techniques. However, BMI is a good surrogate for body fat in 
obesity in large epidemiological sample sizes (Freedman DS. Et al., 2009). The final 
limitation was the lack of a control group. It would, however, be difficult to choose a 
good control group for our purpose. Our population was followed in a tertiary care 
center, and a healthy population of schoolchildren would not be completely comparable 
in terms of chronic stress. Conversely, the strength of the study was the large sample 
size, the measurement of post-challenge glucose levels, and the evaluation of many 
confounding factors. 
Conclusions 
In summary, we have shown that obese children and adolescents with cardiovascular 
risk factors have higher ACTH and cortisol levels, although still within the normal range. 
These findings have led to the hypothesis that the HPA is involved in obesity 
comorbidities early in life and in a broad population. Higher ACTH levels are specifically 
associated with higher triglyceride levels and hyperglycemia, whereas higher cortisol 
levels are specifically associated with hypertension and high LDL-cholesterol levels. 
These specific associations suggest complex mechanisms between the HPA axis and 
metabolic impairments in obesity. 
3. Conclusions 
Overweight and obesity are a major public health concern both in adults and in children 
as stated by the World Health Organization. In fact, childhood obesity is most strongly 
associated to insulin resistance with an increased prevalence of type 2 diabetes, 
dyslipidemia and hypertension at the pediatric age, developing to an increased 
cardiovascular mortality in adulthood. The prevalence of obesity in children and 
adolescents has increased over several decades in many industrialized countries 
(Wang Y. et al., 2006). The southern countries of Europe, surrounding the 
Mediterranean, show prevalence rates for overweight children in the range 20–40%, 
while those in northern areas show rates in the range 10–20% (Lobstein et al., 2003). 
In Italy, the “OKkio alla SALUTE” project demonstrated a high level of childhood obesity 
in the overall population, 23,6% of overweight and 12,3% of obesity, which was higher 
than that of most Western countries; furthermore there were substantial geographic 
differences, with the prevalence of obesity twice as high in the south as in the north. 
Among many potential factors, derangement of multiple hormone systems have 
increasingly been considered for their potential importance in the pathophysiology of 
obesity and metabolic alterations. 
Ghrelin has an emerging role on appetite, glucose and lipid metabolism, and body 
composition and has provided an important strength to this research field opening new 
perspectives within neuroendocrinology and metabolism. In particular it is the only 
known appetite-stimulating hormone in humans and seems one of the principal factors 
involved in appetite, craving and regain weight after weight-loss (Adams CE. et al., 
2011, Delhanty PJ. et al., 2012 ). As anticipated, circadian ghrelin secretion is 
profoundly modulated by acute variations in the energy balance and nutritional status. 
However, the mechanisms mediating the metabolic control of ghrelin secretion are at 
present still matter of debate. Overall, published data suggest that ghrelin acts to 
optimize energy metabolism in period of food restriction as well as preparing the 
metabolism to percept and use fuel. There is increasing evidence that some of ghrelin 
changes may contribute to the regulation of food intake and weight also in children, 
starting from neonates, but these data are not conclusive. Our first three studies 
investigate the role of ghrelin system in paediatric age. The first study demonstrates 
that obese children show AG and UAG levels lower than those in normal weight 
children; this reduction is similar between the two forms, with maintenance of the same 
AG/UAG ratio. We observed that ghrelin levels are lower during puberty in both groups, 
with no differences emerging for gender. Interestingly, when the two ghrelin forms were 
evaluated separately, a peculiar yet strong relationship between UAG levels and 
metabolic parameters has been observed, suggesting a significant role for UAG in 
metabolic functions. The second study is mainly focused on a physiological 
investigation of the two forms of ghrelin, AG and UAG, in healthy AGA newborns 
compared with later in life. The results demonstrate that in full-term NN, the venous 
cord blood at birth presents a very different profile of the two ghrelin forms compared 
with that found in children. NN show lower AG and higher UAG levels than NW and OB 
children, independent of pubertal status. As a consequence, the AG/UAG ratio in cord 
blood of NN is lower compared with that found in NW and OB children. Further studies 
should be performed to clarify the exact role of different ghrelin forms in fetal and 
postnatal life. 
Our third study aim to investigate the contemporary dynamics of AG, UAG and OBST 
after OGTT administration in pediatric obesity with respect to insulin resistance, indices 
of beta-cell function and metabolic alterations that cluster in MS. The results show that 
UAG, AG and OBST are all inhibited by glucose load but with particular patterns and 
each associated with different factors. Specifically, post-OGTT UAG levels are 
associated with insulin sensitivity, while conversely, AG associates with compensatory 
insulin secretion and the insulinogenic index. OBST is associated with glucose and 
compensatory insulin secretion. Metabolic alterations that cluster with MS are not 
associated with UAG and AG, whereas HDL-cholesterol correlates with glucose-
induced OBST secretion. Further investigations to be performed will explain whether 
these secretory profiles could be features of adulthood, as well as their physiological 
significance. 
Also cortisol has been reported to have a role in obesity, hypertension, and the altered 
glucose and lipid profile in Cushing’s syndrome, and some studies have suggested that 
moderately increased morning fasting cortisol may be associated with the presence of 
cardiovascular risk factors in adults (Whitworth JA. Et al., 1995, Pasquali R. et al., 
2008, Sukhija R. et al., 2006). A series of studies in adults and a few studies in 
selected groups of adolescents, have shown alterations in cortisol in individuals with 
cardiovascular risk factors (Anagnostis P. et al. 2009, Reinehr T. et al. 2004, Barat P. et 
al., 2007). In our fourth study we have shown that obese children and adolescents with 
cardiovascular risk factors have higher ACTH and cortisol levels, although still within 
the normal range. These findings have led to the hypothesis that the HPA is involved in 
obesity comorbidities early in life and in a broad population. Higher ACTH levels are 
specifically associated with higher triglyceride levels and hyperglycemia, whereas 
higher cortisol levels are specifically associated with hypertension and high LDL-
cholesterol levels. These specific associations suggest complex mechanisms between 
the HPA axis and metabolic impairments in obesity. 
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5. APPENDIX 
Appendix 1. 
Tanner Stages in females (left panel) and in males (right panel)
Appendix 2a. 
Italian percentiles (2-20 years) in females: height and weight; 
(Cacciari E. et al., 2006). 
Appendi 2b.  
Italian percentiles (2-20 years) in males: height and weight; 
 (Cacciari E. et al., 2006). 
Appendix 2c.  
Italian percentiles (2-20 years) in females: BMI; 
(Cacciari E. et al., 2006). 
 
Appendix2d.  
Italian percentiles (2-20 years) in males: BMI; 
 (Cacciari E. et al., 2006). 
Appendix 3. 
Waist circunference at  90° percentile; 
















(cm)                       
al 90° percentile 
5 55,6 5 55,4 
6 57,1 6 57,0 
7 58,8 7 58,7 
8 60,9 8 60,4 
9 63,2 9 62,0 
10 65,6 10 63,6 
11 67,9 11 65,4 
12 70,4 12 67,3 
13 73,1 13 69,1 
14 76,1 14 70,6 
15 79,0 15 71,7 
16 81,8 16 72,6 
Appendix 4a. 
Blood pressure  percentiles in females; 
(National High Blood Pressure Education Program Working Group  
on High Blood Pressure in Children and Adolescents, 2004). 
Appendix 4b. 
Blood pressure percentiles in males 
(National High Blood Pressure Education Program Working Group  
on High Blood Pressure in Children and Adolescents, 2004). 
Appendix 5.  
Standard Neonatali Italiani: peso (Kg);  
(SEP: Montecatini, 1996). 




soggetti 3° 10° 25° 50° 75° 90° 97° 
                femmine 
26 21 0,572 0,590 0,662 0,776 0,889 0,962 0,979 
27 24 0,566 0,629 0,734 0,875 1,015 1,120 1,184 
28 24 0,605 0,709 0,842 1,1007 1,171 1,304 1,409 
29 27 0,683 0,823 0,981 1,166 1,352 1,510 1,650 
30 62 0,795 0,967 1,146 1,349 1,552 1,732 1,903 
31 67 0,936 1,133 1,331 1,550 1,768 1,966 2,164 
32 93 1,099 1,318 1,532 1,763 1,995 2,208 2,428 
33 125 1,278 1,516 1,742 1,985 2,227 2,453 2,691 
34 270 1,469 1,721 1,957 2,209 2,461 2,698 2,949 
35 441 1,665 1,927 2,172 2,432 2,692 2,936 3,198 
36 917 1,861 2,130 2,381 2,647 2,914 3,165 3,434 
37 2208 2,051 2,323 2,579 2,851 3,123 3,379 3,651 
38 5819 2,229 2,502 2,761 3,038 3,315 3,574 3,847 
39 12007 2,389 2,661 2,921 3,203 3,484 3,745 4,016 
40 16421 2,527 2,794 3,055 3,341 3,627 3,888 4,155 
41 7400 2,636 2,896 3,157 3,447 3,737 3,999 4,259 
42 1863 2,710 2,961 3,222 3,517 3,812 4,073 4,324 
43 252 2,744 2,984 3,245 3,545 3,845 4,105 4,346 
         maschi 
26 20 0,639 0,657 0,730 0,843 0,957 1,029 1,047 
27 26 0,639 0,702 0,807 0,948 1,088 1,193 1,257 
28 29 0,683 0,787 0,921 1,085 1,249 1,383 1,487 
29 44 0,767 0,907 1,065 1,250 1,435 1,593 1,734 
30 51 0,884 1,056 1,235 1,438 1,641 1.821 1,992 
31 77 1,030 1,228 1,426 1,644 1,863 2,060 2,258 
32 99 1,199 1,418 1,632 1,863 2,095 2,308 2,328 
33 154 1,384 1,621 1,847 2,090 2,333 2,559 2,796 
34 297 1,580 1,831 2,068 2,320 2,572 2,808 3,060 
35 492 1,781 2,043 2,288 2,548 2,808 3,053 3,315 
36 1167 1,982 2,251 2,502 2,769 3,035 3,286 3,555 
37 2551 2,178 2,450 2,706 2,978 3,250 3,506 3,778 
38 6494 2,361 2,634 2,893 3,170 3,447 3,706 3,979 
39 12657 2,527 2,798 3,059 3,341 3,622 3,883 4,154 
40 16267 2,670 2,937 3,198 3,484 3,770 4,032 4,298 
41 7297 2,784 3,044 3,306 3,596 3,886 4,148 4,408 
42 2034 2,864 3,115 3,376 3,671 3,966 4,227 4,478 
43 227 2,903 3,144 3,404 3,704 4,004 4,265 4,505 
 
Appendix 6.  
 National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) 








 NCEP ATP III (2004) 
Cruz e Goran  
Central Obesity Waist circunference:  90° percentile 
by age and sex. 
Hypertension: Blood pressure 
systolic or diastolic:  90° percentile by age and sex. 
Dislipidemia: Triglicerides:  90° percentile 
By age and sex. 
HDL Cholesterol (High Density Lipoprotein): 
 10° percentile by age and sex 
Disglycemia: Fasting glucose:  100 mg/dL 
or 
after OGTT (Oral Glucose Tolerance Test): 
 140 mg/dL and < 200 mg/dL. 
  
Appendix 7 
The BMI standard deviation score (BMISDS), sex and age dependent; 
(Cacciari E. et al., 2006) 
 
 
 
 
 
 
 
